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ABSTRACT 
The detection of cancer biomarkers is of great importance in oncology. Cancer biomarkers 
can provide diagnostic information which can aid disease screening and early diagnosis. Further, 
cancer biomarkers can help predict disease prognosis and response to therapy, and also help in the 
monitoring of disease. Thence, the accurate and sensitive detection of cancer biomarkers which 
may be present at very low concentrations is of great clinical importance. Traditionally, these 
biomarkers have been detected predominantly by Enzyme Linked Immunosorbent Assay. The 
traditional biomarker detection assays generally require multiple washing steps, long assay times, 
and have the need for trained expertise and expensive instrumentation. In this dissertation, Lateral 
Flow Strip Biosensors (LFSB) that provide rapid, low-cost and user-friendly screening of cancer 
biomarkers are discussed. The developed biosensors have the added advantages of being portable, 
sensitive and highly selective, which makes them ideal for routine cancer screening. Gold 
nanoparticles (GNP)-based Lateral Flow Strip Immunosensors (LFSI) that colorimetrically 
detected carbohydrate antigen (CA 19-9) and carcinoembryonic antigen (CEA) were developed 
for the screening of human plasma and pancreatic cyst fluid, respectively. Further, carbon 
nanotube based-LFSBs that targeted CA 19-9 and CEA were developed. The CNT-based LFSBs 
showed improved detection limits over the conventional GNP-based LFSB. A GNP-based LFSB 
was also developed for the detection of exosomes using an aptamer that targeted a cell surface 
protein, epithelial cell adhesion molecule (EpCAM). The developed assays showed good 
performance and were used for the screening of pancreatic cancer patient samples. Upon further 
development, the assays discussed in this dissertation could find application in the clinical 
screening and monitoring of cancer, especially in limited resource settings.  
. 
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1. INTRODUCTION 
This dissertation discusses the development of lateral flow strip biosensors (LFSB) for the 
sensitive and selective detection of cancer biomarkers. The LFSBs introduced in this work 
concentrate on the detection of biomarkers for pancreatic cancer. Biomarkers are defined as 
biological processes or molecules whose presence in blood or other body fluids is a sign of a 
normal or diseased condition.1 Biomarkers encompass biomolecules such as nucleic acids (DNA, 
RNA, miRNA), proteins, carbohydrates and exosomes amongst others. DNA biomarkers can 
include single nucleotide polymorphism, chromosomal aberrations, alterations in copy numbers 
and methylation patterns of DNA.2 With advancement in next generation sequencing various types 
of RNA(miRNA, circRNA, snoRNA, IncRNA, piwi,RNA) have been used as biomarkers for 
cancers and other diseases.3 Cell surface receptors, secreted proteins like insulin, phosphorylation 
site patterns, secreted peptides are types of protein biomarkers that have been used for diagnostics 
and monitoring diseased conditions. Processes such as elevated cell death or proliferation may also 
serve as biomarkers.4 The up or down regulation of these biomarkers can be monitored to give 
information for the diagnosis and prognosis of diseases, and for monitoring of response to therapy 
especially for cancer treatment. These biomarkers play an important role at all stages of cancerous 
disease progression and can give insights to treatment regiments best required.5 The levels of 
cancer biomarkers can be used to stage cancers. The early detection of cancers like those of the 
prostate, colon, pancreas, breast etc. can meaningfully increase the survival rate of patients.  
Traditionally, bulk protein detection has been done by colorimetric assays where proteins 
react with chemical agents to produce colored products whose intensities can be quantified by 
spectroscopic methods.6 Techniques like gel electrophoresis, western blot, mass spectrometry give 
more specificity in detection. Immunoassays, particularly Enzyme Linked Immunosorbent Assay 
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(ELISA) is the most popularly used method for protein detection. ELISAs offer acceptable 
specificity and selectivity, however, there are major draw backs such as the need for skilled labor, 
batch to batch differences in antibodies, need for refrigeration, multiple wash steps and the use of 
expensive equipment. These shortcomings reduce ELISA applicability in settings with limited 
resources especially in the developing world. There has therefore been the need to development 
rapid, low-cost, user friendly but sensitive assays that can be used in limited resource settings.  
1.1. Point-of-Care Devices 
It is of immense clinical importance to be able to perform bedside testing and detection of 
disease biomarkers. This helps with prompt diagnosis and initiation of required therapeutic 
intervention. Pont-of-care devices (POCD) allow clinicians to perform diagnostic and prognostic 
assays in close proximity to patients without the use of costly or complicated devices.7  
POCDs offer numerous advantages over the conventional immunoassays which are 
summarized below:  
• Portability: With POCDs patients can self-test in the convenience of their homes. 
This removes the need for transporting patients to medical laboratories for routine 
testing. POCDs are usually miniaturized to ensure their use infield without the need 
to transport samples to a laboratory for testing. Results can be obtained infield and 
appropriate action (treatment or referral for further evaluation) taken. 
• Low Cost: POCDs are developed to be inexpensive for the end users. Cost of 
medical testing and assay kits continues to be a hindrance to healthcare delivery 
globally. With POCDs, medical testing can be done at comparatively lower cost 
compared to conventional tests like ELISA. An ideal POCD does not require the 
use of expensive machinery for assay performance and assay readout. This helps 
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improve access to health screening for low income homes especially in the 
developing world where millions of people die each year from infectious diseases 
like malaria, AIDS etc. 
• Simplicity: The hallmark of POCDs is their nonrequirement for skilled personnel. 
The devices are expertly designed to ensure that end users can effectively use the 
devices by following a simple set of defined steps. Data output for POCDs device 
do not require complex analysis are easy to interpret by an untrained person. 
• Short Assay Times: In emergency situations being able to have quick patient test 
results can be the difference between life and death. POCDs can be invaluable is 
such settings. Assay times can be as short as 15 minutes (mins). This can also help 
reduce patient anxiety as they await test results.  
An idealized concept of a POCD is shown in Figure 1.1.8 An ideal POCD would be a 
disposable device that quantitatively detects multiple targets in as little as 1 µL of sample.9 This 
device would detect target analyte with high sensitivity whilst eliminating cross contamination and 
false positive results. The device would be water proof, storable over a wide temperature range 
and rugged enough to resist damage from small drops.9 The ideal POCD does not exist yet, 
however the forgoing provides a framework to guide research and development efforts to help 
achieve an ideal POCD. 
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Figure 1.1. Idealized concept of a POCD 8. 
1.1.1. Point-of-Care Device Setup 
POCDs like all biosensors consist of three basic components (bioreceptor, transducer, 
signal processor) as shown in Figure 1.2.10 The bioreceptor detects the presence or activity of 
target analyte and gives a measurable signal that can be transduced for the end user to observe. 
The setup can have built-in systems to help amplify the measured signal for more sensitive 
detection. 
Various biorecognition elements like antibodies, enzymes, nucleic acids, proteins and 
microorganisms have been used in the development of biosensors. These serve as bioreceptors that 
interact with target analyte in sample. These interactions are coupled to transducers that give off 
measurable signal. Biosensors are very versatile and have been coupled with electrochemical, 
colorimetric, chemiluminescence and piezoelectric transducers over the years. 
The most popular POCD that has found universal acceptance is the electrochemical glucose 
sensor. Since the successful commercialization of the glucose meter, lateral flow strip biosensors 
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have also found wide use and acceptance. The most popular of which is the home-based pregnancy 
test strip which tests for the presence of human chorionic gonadotropin (HCG) in urine.  
 
 
Figure 1.2. Components of a biosensor 10. 
1.2. Lateral Flow Strip Biosensors 
Lateral flow strip biosensors (LFSB), also referred to as dip stick biosensors are 
chromatographic test strips that traditionally give yes/no results for presence or absence of target 
analyte. The setup for the LFSB is as shown in Figure 1.3. The device consists of 4 main zones 
(i.e. sample pad, conjugate pad, nitrocellulose membrane and the absorption pad) all assembled on 
a sticky backing layer. The sample pad is a cellulose membrane that serves as the sample 
application zone. The sample pad is porous and allows the sample to travel through it. Sample pad 
pores must be appropriately sized to allow the movement of various targets (e.g. proteins, nucleic 
acids, cells and other small molecules etc.). This pad can be treated with buffers to enhance the 
performance of the LFSB. The treatment can serve to improve the separation of sample 
components, enhance continuous flow, remove interferences and also ensure optimal pH.11 The 
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conjugate pad is usually made of a glassy fiber, that can soak up reasonable volume of conjugate 
(biorecognition elements linked to a suitable transducer). The conjugate pad should be capable of 
keeping the conjugate stable over the shelf life of the LFSB and release dried conjugate in the 
presence of buffer. The most popular transducer used for LFSB is the gold nanoparticle (GNP) 
because of its surface plasmon properties and ease of synthesis. The nitrocellulose membrane 
supports the test and control lines. Various nitrocellulose membranes exist with varying membrane 
pore size and thus different flow rates. The flow rates dictate the time frame for interactions 
between test line biorecognition elements and target analyte. The test lines and control lines are 
dispensed with specialized equipment to give consistent volumes per unit area of nitrocellulose 
membrane. The final zone is the absorption pad which is made up of cellulose fiber. The absorption 
pad wicks the reagents as the assay progresses to enhance capillary action across the strip. All 
components are assembled on the sticky backing layer such that they overlap to ensure continuous 
solvent flow. 
  
 
Figure 1.3. Setup of the lateral flow strip biosensor. 
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1.2.1. Biorecognition Elements for Lateral Flow Strip Biosensors 
The sensitivity of any biosensor sterns mostly from the quality of biorecognition element 
used to make the sensor. Traditionally, antibodies have been used as the biorecognition elements 
for LFSBs. When antibodies are used as biorecognition elements for LFSBs, the biosensors are 
referred to as Lateral Flow Immunoassays (LFI). Antibodies have long been used in immunoassays 
and their sensitivity and selectivity are well reported. Two antibody classes (monoclonal and 
polyclonal) have been used on LFSBs. Monoclonal antibodies bind to a single epitope on the 
surface of the targets while polyclonal antibodies bind to multiple epitopes. Both types of 
antibodies have been used for the development of LFSBs. However, batch to batch variation, need 
for cold storage, and to a lesser extent cross-reactivity can limit the performance and applicability 
of antibodies for the development of POCDs. 
A class of ligands called aptamers have gained increased attention in recent years and have 
been used in place of antibodies for the preparation of various biosensors. Aptamers are nucleic 
acids that can fold up into unique structures and are able to bind selectively to target molecules. 
Aptamers are developed through a procedure termed Systematic Evolution of Ligands by 
Exponential Enrichment which was first reported independently by two research groups.12,13 
Aptamers are inexpensive to synthesize, highly selective, easy to chemically modify and have the 
added advantage of being easy to synthesize. Aptamers have been reported for various targets 
including protein biomarkers. On LFSBs, aptamers have been used for the detection of proteins14, 
cells15, bacteria16 and some small molecules17. Other biorecognition elements used to a lesser 
extent for the development of LFSBs include bacteriophages and proteins.  
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1.2.2. Nanomaterials for Lateral Flow Strip Biosensors 
LFSBs can be developed to give colorimetric, fluorescent, chemiluminescent and 
electrochemical signals that can be used for qualitative and quantitative measurement of target 
analyte. Nanoparticles are usually employed to help give out these measurable signals. The 
nanoparticles also serve as carriers that support biorecognition elements that give the assays their 
specificities. Other substances like enzymes can also be coupled to nanoparticles as a form of 
signal enhancement. 18 
Gold nanoparticles (GNP) are the gold standard for lateral flow strip biosensors. GNPs are 
easy and inexpensive to synthesize. They are also stable for extended periods under refrigeration. 
GNPs are easily linked to thiol groups by thiol self-assembly. They may also be linked to 
antibodies by physical adsorption. GNPs, because of their surface plasmon properties have an 
intense size dependent red color. This makes them ideal for colorimetric LFSB applications. GNPs 
have been used for the detection of proteins18, cells15, nucleic acids19,20 and other small molecules 
21,22. Gold nanoparticles have also been coated on silica nanorods for the detection of nucleic 
acids23 and proteins 24. 
Carbon nanotubes are also attractive materials for lateral flow assays development. CNTs 
have the advantages of having intense black color to aid colorimetric detection and have a large 
surface area because of their high aspect ratio which enables the attachment of numerous 
biorecognition elements. Acid treated CNTs have carboxyl functionalization on their surface that 
aids the covalent attachment of biorecognition elements. CNT’s have been used for the detection 
of nucleic acids25. Magnetic carbon nanotubes based LFSBs have also been reported for the 
detection of proteins 26 and carbohydrate antigen (CA 19-9) 27 in whole blood. 
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Liposomes, which are spherical vesicles that are integrated by one or more phospholipid 
bilayers have also been applied on lateral flow strip biosensors. The membrane of the liposome 
can be modified with biorecognition elements and the interiors of the liposomes may contain 
colored dyes for colorimetric assays and enzymes for colorimetric enhancement and 
chemiluminescent assays.28,29 Ho and Wauchup developed a liposome based LFSB for the 
detection of Aflatoxin B1.30 In this assay the liposomes encapsulated a visible dye that aided 
colorimetric detection to target Aflatoxin B1. Liposomes have been used for detection of other 
targets like nucleic acids28 and proteins31.  
Fluorescent nanoparticles and dyes have also found wide application as transducers on 
LFSBs. The use of quantum dots, fluorescent quenching materials, upconverting nanoparticles and 
lanthanide chelate labels have been reviewed. 32 
Other nanoparticles like magnetic nanoparticles, latex nanoparticles, silica nanoparticles 
and platinum (Pt) nanoparticles have been applied with varying degrees of sensitivity on the LFSB 
platform.32 
1.2.3. Lateral Flow Strip Biosensor Formats 
The most popular format of the LFSB is the sandwich type immunoassay. This format is 
similar to conventional sandwich immunoassays like ELISA. Here, a target molecule is captured 
between a primary capture antibody immobilized as test line and a secondary detection antibody. 
The secondary antibody is conjugated to a suitable transducer and its accumulation on the test line 
increases with increasing concentration of target molecule. The formation of the sandwich is 
dependent on the presence of the target molecule as the target serves as a bridge between the 
capture and detection antibodies. As shown in Figure 1.4, the accumulation of the conjugate on 
the test line results in the formation of a colored line which can be visually observed for yes/no 
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results. The more intense the color, the higher the concentration of target in test sample. Excess 
conjugates are captured by the pre-immobilized antibodies on the control line. When transducers 
like quantum dots, fluorescent dyes and electrochemically active species are used, the measured 
signal which increases with increasing amount of target can be fluorescent or electrochemical.  
 
Figure 1.4. Sandwich format lateral flow assay (image modified from reference11). 
The second format of the lateral flow assay follows the competitive format, also known as 
signal-off format. In this setup as shown in Figure 1.5, target competes with conjugates for binding 
to the test line biorecognition element. In the presence of target, the target preferentially binds to 
the test line thereby preventing conjugates immobilization on test line. Subsequently, the higher 
the concentration of target analyte in test sample the lesser the intensity of the signal observed on 
the test line. The excess conjugate is captured on the control line to validate the assay.  
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Figure 1.5. Competitive lateral flow assay (image modified from reference11). 
A second type of competitive LFSB format has labelled analyte conjugated to a transducer 
and dispensed on the conjugate pad. A detection antibody is dispensed as the test line. Test solution 
will contain free unmodified target analyte which competes with the conjugated analyte on the 
conjugate pad for binding to the test line antibody. 
1.3. Applications of Lateral Flow Strip Biosensors 
LFSBs represent a very versatile platform and have found applicability across different 
industries as summarized by Figure 1.6. LFSBs have been applied for the detection of proteins, 
nucleic acids, cells and pathogens of clinical, veterinarian and food safety importance. Heavy 
metals, pesticides and other small molecules of agricultural and environmental safety concern have 
also been detected on LFSB.  
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Figure 1.6. Applications of lateral flow strip biosensors. 
1.3.1. Protein Detection on Lateral Flow Strip Biosensors 
Proteins are of importance in a variety of fields. In medical and veterinarian disciplines 
proteins serve as biomarkers for diseased conditions. The most widely used application of LFSB 
for protein detection is the home-based pregnancy test kit that detects HCG presence in urine of 
expectant mothers. Other proteins like fatty acid binding protein33 and cardiac troponin34,35 which 
are markers for cardiac diseases have also been detected with LFSBs. A surface-enhanced raman 
scattering LFSB was developed for the detection of prostate specific antigen (PSA), a marker for 
prostate cancer, was reported with acceptable sensitivity and selectivity.36 Carcinoembryonic 
antigen (CEA) and neuron specific enolase (NSE) which can serve as markers for small cell lung 
cancer were simultaneously detected using magnetic nanobeads based LFSB.37 Other proteins like 
albumin38, C-reactive protein39,40, and lipoprotein A41 have also been detected in whole blood and 
plasma for the diagnosis of various metabolic disorders. LFSBs have also found application in the 
detection of allergenic food proteins as reviewed.42 
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1.3.2. Nucleic Acid Detection on Lateral Flow Strip Biosensors 
Nucleic acids can serve as potent biomarkers for various cancers, infectious diseases and 
genetic disorders. Detecting nucleic acids in clinical samples is of immense importance in the 
medical field. There has been research over the years to develop LFSB based assays for the 
detection of nucleic acids. Nucleic acid hybridization dynamics is more complex and differs from 
that of immunoreactions. The initial nucleic acid biosensors relied on the detection of hapten 
modified nucleic acid amplification products using antibodies and hapten-protein complexes.43 
Other reports performed nucleic acid hybridization reactions in buffers prior to applying them on 
the LFSBs for detection.29,44 Mao and coworkers19 introduced a GNP based LFSB for the visual 
detection of DNA. This biosensor did not require prior incubation of DNA sequences before 
application on the LFSB, thus reducing the assay time significantly. Since then there has been 
direct detection of nucleic acids on the LFSB without the need for nucleic acid amplification.23,25,45 
Nucleic acid detection on LFSBs have been used for the detection of bacteria29,44, viruses46–49, 
plasmodium50 and cancer related miRNA23,51. Additionally, LFSBs have aided the nucleic acid 
based identification of genetically modified organisms52,53, chromosomal translocation20, and 
genotyping of single-nucleotide polymorphisms54. 
1.3.3. Lateral Flow Strip Biosensor Based Detection of Cells and Exosomes  
The detection of cells and exosomes is of importance in disease diagnosis, especially in 
cancer and infectious diseases. Measuring of circulating cancer cells and exosomes may help in 
the monitoring of patient response to therapy. Biomarkers that are displayed on the surface of cells 
and exosomes can be targeted using antibodies and aptamers for the detection of associated 
exosomes or cells on lateral flow strip assays. A lateral flow immunoassay (LFI) was reported for 
the detection of human pluripotent stem cells using antibodies that targeted surface proteins, stage-
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specific embryonic antigens 3 and 4.55 In other reports, whole bacteria like Escherichia coli56 and 
Salmonella enteritidis57 were detected in food including milk powder, flour, starch and eggs. 
Whole Yersinia pesti which causes bubonic plaque was also detected using an antibody aided 
lateral flow strip test.58 Li and coworkers59 also reported a multiplexed LFI for the simultaneous 
detection of Pseudomonas aeruginosa and Staphylococcus aureus using colloidal gold as nano-
labels. 
The examples cited thus far have relied on antibodies as biorecognition elements. Not much 
work has been done on the detection of cancer cells and exosomes using aptamer based LFSBs. 
Mao and coworkers15 detected Ramos cells in a sandwich assay using a thiolated aptamer linked 
to a GNP and a second biotinylated capture aptamer immobilized on a solid support (nitrocellulose 
membrane). The GNP accumulation on the test line correlated with Ramos cell numbers. The assay 
was subsequently used to detect Ramos cells spiked into blood samples. Bacteria of food safety 
concern were also detected using aptamer based LFSBs.16 
1.3.4. Lateral Flow Strip Biosensor Based Detection of Other Small Molecules 
The LFSB platform has been used for the detection of small molecules of importance 
across medical, food safety and agricultural industries. Metal ions for example can play important 
biological functions by serving as co-factors for enzymes and as structural components of 
biomolecules such as hemoglobin. Other metals such as Mercury (Hg), lead (Pb), cadmium (Cd) 
can be toxic to living organisms. LFSBs for the detection of Pb2+ 60 and Cu2+ 61 were developed 
using non-cross-linked gold nanoparticle–DNAzyme conjugates. Other heavy metal such as Hg2+, 
and Cd2+ have also been detected using nanogold labels.21,62 
In the food and beverage safety industry toxins produced by various microbes and fungi 
are of critical heath and food safety concern. Mycotoxins like aflatoxin and ochratoxin that have 
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oncogenic properties have been detected on lateral flow strips.63–65 In other work, drugs like 
clenbuterol 66, aminohydrantoin 67, and toxins like T2-Toxins 68 have also been detected in farm 
produce using LFSBs. 
In the agricultural industry the use of pesticides and weedicides is important for increasing 
animal and crop survival and produce quality. However, if these chemicals are not regulated, they 
can remain in food produce and have harmful effects on the consumers. It is therefore important 
to measure these chemicals in foods to ensure the safety of the consumers. A reagentless LFSB 
was developed for the detection of acetylcholinesterase inhibitors and organophosphate 
pesticides69 in beverage and food samples. Other pesticides like carbofuran and triazophos22, 
carbaryl and endosulfan70 have been detected in agricultural produce using multiplexed lateral 
flow assays. To assess exposure to pesticides, a lateral flow strip assay was developed for testing 
the presence of trichloropyridinol (a biomarker of exposure to chlorpyrifos) in human plasma.71 
1.4. Aims and Objectives of this Study 
The aim of this dissertation is to develop simple, rapid, low cost and user-friendly 
biosensors for the detection of cancer biomarkers to facilitate disease screening and monitoring. 
Clinically, the detection of biomarkers in bodily fluids can help in the early diagnosis of diseases 
ranging from genetic disorders, various cancers, infectious diseases and exposure to pesticides and 
other chemicals. Measuring of protein biomarker levels can also help monitor patient response to 
therapy. This can help physicians adjust drug treatment regiments to ensure higher survival rates 
of patients. For example, pre-surgery and post-surgery levels of a biomarker like CA 19-9 can be 
used to monitor the success of the surgery and confirm remission of pancreatic cancer. 
For pancreatic cancer, CA 19-9 and CEA are the most popular markers used for monitoring 
disease and response to therapy and surgery. They have been predominantly measured by ELISA. 
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Though ELISAs offer acceptable sensitivity and selectivity they have the disadvantages of 
requiring expensive washers and readout spectrophotometers, and skilled labor. ELISA usually 
has multiple wash cycles and long incubation times (a few hours to overnight incubation) that can 
result in long assay times. On the contrary, lateral flow assays offer a quick, inexpensive and 
simple alternative to the traditional ELISA tests. Lateral flow assays require low sample volumes 
but achieve good sensitivity and selectivity. This dissertation seeks to discuss the development of 
LFSBs for the detection of cancer biomarkers directly and indirectly from pancreatic cancer patient 
samples.  
• A rapid and sensitive GNP-based LFSB was developed for the quantitative 
detection of CA 19-9 in human plasma. The visual detection limit of the assay was 
5ng mL-1 which was below the reference value (37 U mL-1). The assay was 
successfully used to detect CA 19-9 in human plasma and assay results were 
validated with commercial ELISA test kits. 
• A quantitative and rapid GNP-based LFSB was developed for the detection of CEA 
in human pancreatic cyst fluid. The developed assay had good sensitivity with 
detection limit of 2 ng mL-1. The assay was successfully used to distinguish 
mucinous from non-malignant pancreatic cyst.  
• A MWCNT-based LFSB for ultrasensitive detection of proteins in human plasma 
was developed. Combining the advantages of lateral flow assays with the unique 
physical properties of CNT (color, high aspect ratio and ease of surface 
modification), the optimized LFB had a detection limit 1.32 pg mL-1 of rabbit IgG. 
This detection limit was 3 orders lower than the detection limit of the GNP-based 
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LFSB for rabbit IgG detection. The assay was successfully used for the detection 
of rabbit IgG spiked in human plasma. 
• Based on the improved sensitivity of the MWCNT-based LFSB developed for 
protein detection in human plasma, a MWCNT-based LFSB was developed for the 
screening of CEA. The assay showed improved detection limits of 0.1 ng mL-1 
relative to CEA detection on GNP-based LFSB with detection limit of 2 ng mL-1. 
• A MWCNT- based LFSB was developed for the detection of CA-19-9. The 
developed biosensor showed good sensitivity with a visual detection limit of 0.14 
U mL-1 CA 19-9 in buffered solution, which was an about 35-fold improvement 
over the GNP-based LFSB for CA 19-9 detection. Further, it showed a linear 
dynamic range of 5 to 100 U mL-1 CA 19-9. 
• A lateral flow strip aptasensor (LFSA) was developed for the quantitative detection 
of pancreatic cancer exosomes using GNP as colorimetric labels. The assay targeted 
an exosome surface protein (EpCAM), whose expression changes in pancreatic 
cancer patients. The developed assay had a low detection limit of 1.3 x 103 
exosomes µL-1 which was over 60-folds lower than a previously reported antibody 
based LFSB for exosome detection.72  
  
 18 
2.  DEVELOPMENT OF QUANTITATIVE IMMUNOCHROMATOGRAPHIC ASSAY 
FOR RAPID AND SENSITIVE DETECTION OF CARBOHYDRATE ANTIGEN 19-9 
(CA 19-9) IN HUMAN PLASMA† 
2.1. Introduction 
Changes in the levels of various biochemical molecules have been known to be associated 
with diseased conditions for years. These molecules are termed biomarkers and represent a very 
diverse group of molecules including proteins (enzyme, antibodies, cell surface receptors, secreted 
proteins), nucleic acids (DNA, microRNAs), carbohydrates, peptides and other molecules.5 In 
cancer research, biomarkers are used for disease diagnosis, monitoring patient response to therapy, 
post-operative monitoring, progression of disease condition and disease recurrence.5,73 
Carbohydrate antigen sialyl Lewis commonly denoted as CA 19-9, is a cancer biomarker that was 
first isolated in 1979 by Koprowski and coworkers from colorectal carcinoma and later from 
pancreatic carcinoma.74,75 CA 19-9 is the main tumor biomarker for digestive tract associated 
cancers.76–78 The highest CA 19-9 expression has been reported to occur in pancreatic cancer. 79 
CA 19-9 is also associated with other digestive tract cancers, including stomach and bile cancer. 
Others like breast, lung, and ovarian cancers have also been reported to be associated with elevated 
CA 19-9. 80,81 Elevated CA 19-9 has also been linked with non-cancerous conditions such as 
pancreatitis, bile inflammation, cirrhosis and obstructive jaundice disease.80,81 Despite its low 
specificity, CA 19-9 remains the only United States Food and Drug Administration (USFDA) 
                                                 
† The work discussed in this chapter was co-authored by Kwaku Baryeh, Sunitha Takalkar, Michelle Lund and 
Guodong Liu. The work was previously published in the Journal of Pharmaceutical and Biomedical Analysis.119  
Kwaku Baryeh was the primary developer of the conclusions that are advanced here. Kwaku Baryeh drafted and 
revised all versions of this chapter. Sunitha Takalkar, Michelle Lund and Guodong Liu proofread the manuscript and 
helped trouble shoot experimental conditions. 
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approved biomarker for pancreatic cancer and is the most accurate single biomarker for pancreatic 
cancer.82 
Pancreatic cancer is one of the deadliest cancers with a yearly diagnosis rate close to its 
annual mortality rate.83 Hence, sensitive and specific determination of low levels of CA 19-9 in 
biological fluids would be advantageous in clinical diagnosis, prognosis and monitoring of 
pancreatic cancer patient response to therapy.  
A variety of strategies and techniques have been developed to detect CA 19-9. Most of 
these assays utilize CA 19-9 monoclonal antibody 1116-NS-19-9 clone as a specific probe to 
recognize CA 19-9.80 One of the first CA 19-9 assays developed was a radioimmunoassay reported 
in 1983.84 Since then there have been reports of enzyme linked immunosorbent, 
photoelectrochemical, fluorescent and electrochemical assays for detection of CA 19-9.85–87 There 
are also reports of CA 19-9 detection using Surface Plasmon Resonance (SPR) and Raman 
Spectroscopy.88,89 Though most of these methods have provided acceptable detection limits and 
specificities to CA 19-9, there remains drawbacks such as the use of radioactive materials, 
extensive sample preparations and wash steps, enzyme reactions, long assay times and the 
requirement for technical expertise, as well as expensive and specialized instrumentation. 
Immunochromatographic assay (IA), also named lateral flow immunoassay (LFI), is a 
point-of-care approach, which overcomes the drawbacks of traditional immunoassays. Lateral 
flow assays have been used for the detection of various targets ranging from proteins and nucleic 
acids to other small molecules.24,25,45,90–96 Various nanoparticles (e.g. GNPs, quantum dots, silver 
nanoparticles among others) have been used in lateral flow assays with varying degrees of 
sensitivity. GNPs are however the gold standard for lateral flow assays due to their stability, ease 
of preparation and low cost. The surface plasmon property of GNPs gives them intense size 
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dependent coloration, which makes them highly desirable for LFSB applications. The color of 
GNPs enables naked eye detection of analyte on LFSBs. GNPs have shown great versatility for 
use in the analysis of complex matrixes including food, water and clinical samples (e.g. plasma, 
serum). 24,25,90–96 Traditional LFIs are qualitative (Yes/No) or semi-quantitative assays. Recently, 
our group and others have developed quantitative LFSBs for rapid and sensitive detection of 
various analytes.24,25,45,91,94–96 In this work, a quantitative immunochromatographic assay (QIA) 
was developed using a GNP-based LFSB and a portable strip reader for the rapid and sensitive 
detection of CA 19-9 in human plasma. This has the advantages of being rapid, sensitive and low 
cost as compared to the conventional CA19-9 immunoassays and immunosensors. 
2.2. Experimental Section 
2.2.1. Apparatus 
Biojet BJQ 3000 dispenser, Clamshell Laminator, and the Guillotine cutting module CM 
4000 manufactured by Biodot LTD (Irvine, CA, USA) were used to prepare lateral flow strip 
biosensors. Portable test strip reader (DT2032) was purchased from Shanghai Goldbio Tech. Co., 
LTD (Shanghai, China). 
2.2.2. Reagents and Materials  
Gold chloride trihydrate (HAuCl4), trisodium citrate, sodium deodocylsulfate (SDS), 
sodium chloride (NaCl), Tween 20, sucrose, trisodium phosphate (Na3PO4), 
hexadecyltrimethylammonium bromide (CTAB), trizma hydrochloride (Tris-HCl, pH=8.0), 
phosphate buffered saline (PBS, pH=7.4, 0.01M), PBS with 0.05% Tween-20 (PBST, pH=7.4), 
bovine serum antigen (BSA) and immunoglobulin (IgG) from human plasma were obtained from 
Sigma Aldrich (St. Louis, MO, USA). Nitrocellulose membranes (HFC090MC100, 
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HFC180MC100, HFC240MC100), glass fiber (GFCP000800) and fiber pads were (CFSP001700) 
obtained from Millipore (Billerica, MA, USA).  
Native CA 19-9 protein (30-AC14) and mouse anti-CA19-9 antibodies with catalogue 
numbers of 10-CA19A and 10-CA19B were purchased from Fitzgerald Industries International 
(Acton, MA, USA). The anti-CA 19-9 antibodies were designated as anti-CA 19-9 AbA and anti-
CA 19-9 AbB, respectively. Human mammaglobin was purchased from Creative BioMart 
(Shirley, NY, USA). CA 19-9 ELISA kit (EHCA 19-9) and goat anti-mouse IgG (A16092) was 
purchased from Thermofisher Scientific (Waltham, MA, USA). Healthy human plasma samples 
were purchased from Golden West Biologicals, Inc. (Temecula, CA, USA). Blood samples from 
pancreatic cancer patients were provided by Sanford Clinic (Fargo, ND, USA, IRB#: SM17227). 
All reagents used were analytical grade chemicals. All solutions used in the study were prepared 
in ultrapure (>18 MΩ) water made from Milli-Q water purification system by Millipore (Billerica, 
MA, USA). 
2.2.3. Preparation of GNP and GNP- Anti CA 19-9 AbA Conjugates 
GNPs with typical diameters averaging 13 nm ± 3.5 nm were prepared as previously 
reported.97 Briefly, glassware used for the preparation of the GNPs were soaked with aqua regia 
(3:1; HCl:HNO3) followed by thorough washing with distilled water. Fifty microliters of 50% w/v 
HAuCl4 was added to 250 mL ultrapure water in glassware. The mixture was heated and brought 
to boil under vigorous stirring. Sodium citrate solution was added, and the mixture was allowed to 
boil until the characteristic red color of GNPs was observed. The solution was boiled for an 
additional 10 mins. Prepared GNP solution was cooled down to room temperature (RT) and stored 
at 4°C until further used. 
 22 
GNP-Anti CA 19-9 AbA conjugates were prepared by incubating anti-CA19-9A AbA at a 
concentration of 75 µg in 1 mL of 5-fold concentrated GNPs at pH=9. The mixture was incubated 
at RT for 1 hour on a shaker at low speed. After which 10% BSA solution was added to a final 
concentration of 1%. The mixture was further incubated for 1 hour with gentle mixing. The mixture 
was then centrifuged at 12,000 rpm for 15 mins at 4°C. The supernatant containing excess 
antibodies was discarded and pelleted GNP-Anti CA19-9 AbA conjugate was resuspended in PBS 
containing 1% BSA to wash it. The washing was repeated twice, and conjugate was finally 
suspended in a buffer containing 20 mM sodium phosphate, 0.25 % Tween-20, 10 % sucrose and 
5 % BSA. Prepared conjugates were stored at 4°C until used. 
2.2.4. Preparation of CA19-9 Lateral Flow Strip Biosensors 
The setup for the developed GNP-based LFSB is as pictured in Figure 2.1. The biosensor 
was composed of a sample pad, conjugate pad, nitrocellulose membrane and an absorption pad all 
immobilized on a sticky backing layer.  
 
Figure 2.1. Configuration of the gold nanoparticle-based lateral flow strip biosensor for the 
detection of CA 19-9. 
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The sample pad was a cellulose fiber pad (17 mm x 300 mm) and pretreated with a buffer 
(0.05 M Tris-HCl + 0.25% Triton X-100 + 0.15 mM NaCl, pH 8.0) for 1 hr after which it was 
dried at 37◦C and stored in a desiccator at RT until used. The conjugate pad was a glassy fiber 
membrane on which the GNP-Anti-CA19-9 AbA conjugate was dispensed on before an assay. The 
test and control lines of LFSB, which were 3 mm apart, were prepared by dispensing anti-CA19-
9 AbB (0.5 mg mL-1) and goat anti-mouse IgG (1 mg mL-1) respectively onto the nitrocellulose 
membrane (25 mm ×x 300 mm). The nitrocellulose membrane was dried at 37°C for 1 hr and 
subsequently kept at 4°C until used. The absorption pad was a cellulose pad with dimensions 
17mm x 300mm. All components were assembled onto a 60 mm × 300 mm adhesive plastic layer 
with a clamshell laminator. To ensure the continuous migration of solution along the LFSB, the 
components were overlapped by 2 mm. The assembly was then cut down to strips with 3 mm width 
using a Guillotine cutting module CM 4000. Prepared strips were kept at 4°C until used. 
2.2.5. Assay Procedure 
One hundred microliters of CA 19-9 sample solution prepared in running buffer (PBS + 
1% BSA + 0.5 mM CTAB) was applied to the sample pad of the developed LFSB. The solution 
could travel through the membranes in 15 mins. An extra 100 µL of running buffer was added to 
wash the test strip. The washing step removes any nonspecifically adsorbed conjugates and thus 
reduces background signal. The test results could be read visually with the naked eye after 5 mins. 
To get quantitative data, the intensities of the test and control lines were read with a portable test 
strip reader. Human plasma samples were tested with a similar procedure as above. Prior to testing, 
plasma  samples were diluted 2-fold with PBS buffer containing 2% BSA and 1% CTAB. 
Pancreatic cancer plasma samples were prepared by centrifuging blood samples at 3000 x g and 
collecting the supernatant.  
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2.3. Results and Discussion 
2.3.1. Principle of the Quantitative Immunochromatographic Assay (QIA) for CA 19-9 
Figure 2.2 illustrates the principle of the QIA for the detection of CA 19-9. Anti-CA 19-9 
Ab B and goat anti-mouse IgG antibody were pre-immobilized on the nitrocellulose membrane to 
form the test line and control lines respectively. Anti-CA 19-9 Ab A was used as detection antibody 
and was immobilized on the GNP surface. The  GNP-anti-CA 19-9 Ab A conjugate was dispensed 
on the conjugate pad. 
Sample solution containing CA 19-9 was applied on the sample application pad. The 
solution migrated by capillary action, and upon reaching the conjugate pad, rehydrated the GNP-
anti-CA 19-9 Ab A conjugates. An immune-complex (GNP-anti-CA 19-9 Ab A-CA 19-9) was 
formed between the CA 19-9 and anti-CA 19-9 Ab A of the GNP-anti-CA 19-9-AbA conjugates 
and continued to migrate along the strip. The complex was captured on the test zone through a 
second immunoreaction between the CA 19-9 and the immobilized anti-CA 19-9 Ab B. The 
accumulation of GNPs in the test zone was visualized as a characteristic red band (Figure 2.2. a). 
The excess GNP-anti CA 19-9 Ab A conjugates continued to migrate and were captured on the 
control zone by the immune-events between goat anti-mouse IgG and anti-CA 19-9 Ab A. This 
resulted in the formation of a second red band (Figure 2.2. a). In the absence of CA 19-9, no red 
band was observed in the test zone. In this case, a single red band (control line) showed that the 
LFSB was working well (Figure 2.2. b). The strips were observed with the naked eye for 
qualitative analysis. Quantitative analysis is performed by reading the optical intensity of the test 
and control lines with a portable strip reader (Figure 2.2. c). The strip reader connected with a 
laptop which had an installed software that transduced the line intensities into characteristic peaks. 
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The peak area on the computer monitor was proportional to the number of GNPs captured on the 
test line, which was in-turn proportional to the concentration of CA 19-9 in the sample solution. 
 
Figure 2.2. Principle of quantitative immunochromatographic assay of CA 19-9 (a) Capture of 
gold nanoparticles on the test line and control line in the presence of CA 19-9 (b) Capture of gold 
nanoparticles on the control line in the absence of CA 19-9 (c) Measuring the intensities of test 
and control lines with a portable strip reader connected to a laptop computer. 
2.3.2. Optimization of Experimental Parameters 
Assay parameters including the membrane type, antibody concentration, amount of GNP-
anti-CA 19-9 conjugates and the components of the running buffer were optimized to obtain the 
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best sensitivity and reproducibility of the assay. The flow rate of sample solution on the 
nitrocellulose membrane dictated the time frame within which CA 19-9 interacted with the 
antibodies on the GNP surface, test line and control line. Three membranes HF090MC100, 
HF180MC100 and HF240MC100 with flow time of 90, 180 and 240 seconds (sec) as reported by 
the manufacturer were evaluated for their performance in the LFSB. From Figure 2.3. a, it is 
observed that the 90sec membrane had the highest signal to noise (S/N) ratio. Although the 180 
sec and 240 sec membranes increased the immunoreaction time, it led to high background signal 
and hence lowered the S/N ratios. Therefore, the 90sec membrane was chosen to prepare the 
LFSBs. 
 
Figure 2.3. (a) Effect of different types of nitrocellulose membranes on the S/N ratio of the assay 
(b) Effect of the dispensing times of Anti-CA 19-9 AbB on the S/N ratio of the assay (c) Effect of 
buffer components on the S/N ratio of the assay. 
The signal of the LFSB was affected by the amount of anti-CA 19-9-AbB immobilized on 
the test zone, which needed to be enough to generate the test band with minimum nonspecific 
adsorption. The anti-CA 19-9 AbB solution was dispensed on the test zone with different 
dispensing times and the S/N ratios of the LFSBs were compared. As shown in Figure 2.3 b, the 
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highest S/N ratio of the LFSB was obtained when the dispensing times was 2. At dispense times 
of 3 and 4, the S/N ratio reduced. This is most likely the result of increased non-specific interaction 
at high concentration of antibody as well as steric hindrance. Therefore, 2 times dispense cycles 
of the test line was used for further development of the LFSB. 
The composition of running buffer has a substantial influence on the performance of the 
LFSB. Various buffers including PBS + 1% BSA, PBS + 1% BSA + 0.5 mM CTAB, PBST + 1% 
BSA, PBST + 1% BSA + 0.5 mM CTAB, Tris-HCl + 1% BSA and Tris-HCl + 1% BSA + 0.5 mM 
CTAB were tested. It was observed that the highest S/N ratio was obtained with PBS+1% BSA+0.5 
mM CTAB (Figure 2.3. c), which was therefore used as running buffer for subsequent 
experiments. 
The amount of anti-CA 19-9 AbA used to prepare GNP-anti-CA 19-9 AbA conjugates 
played a key role in the sensitivity of the assay. Various concentrations of anti-CA 19-9 AbA were 
used to prepare the conjugates and the S/N ratios of LFSBs were compared (Figure 2.4 a). From 
the graph, low S/N ratios of LFSBs were obtained with low concentrations of antibody. The reason 
could be low coating density of antibody on the GNP surface, which reduced the efficiency of 
immunoreactions during the assay. Beyond 75 µg of antibodies for conjugate preparation, there 
was a reduction in the S/N ratio of the assay. The low S/N ratio at higher concentrations could be 
attributed to overcrowding of the antibodies on the surface of the GNP thus reducing accessibility 
to bind target CA 19-9. As shown in Figure 2.4. a, 75 µg of anti-CA 19-9 AbA gave the highest 
S/N ratio and was thus chosen for subsequent assays. 
 28 
 
Figure 2.4. (a) Effect of the amount of Anti- CA 19-9 AbA used for conjugate preparation on the 
S/N ratio of the assay (b) Effect of the conjugate volume on the S/N ratio of the assay. 
The amount of GNP-anti-CA 19-9 AbA conjugate dispensed on the conjugate pad was also 
optimized to obtain the best sensitivity of the assay. Different volumes of GNP-anti CA 19-9 AbA 
were loaded on the conjugate pad and the S/N ratios of the assay were compared. As presented in 
Figure 2.4 b, the S/N ratio peaked at 4 µL, after which the S/N ratio reduced. Beyond 4 µL of 
conjugate, there was increased background signal due to increased nonspecific adsorption thus 
reducing the S/N ratios. A conjugate volume of 4 µL was adopted for further assay development. 
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2.3.3. Analytical Performance 
Under the optimized experimental conditions, the GNP-based LFSBs were used to detect 
different concentrations of CA 19-9. Sample solutions were prepared by diluting the CA 19-9 stock 
solution in running buffer. All tests were run in triplicates. 
 
Figure 2.5. (a)Photo images of LFSBs in the presence of different concentrations of CA 19-9 (b) 
Calibration curve of CA 19-9 detected on developed GNP-based lateral flow strip biosensor. Each 
data point represents the average value obtained from three different measurements. 
Figure 2.5. a presents the typical photo images of the LFSBs with increasing 
concentrations (0 to 100 U mL-1). As expected, the intensities of the test-lines increased with 
increasing concentrations of CA 19-9. No test line was observed on the test zone of LFSB in the 
absence of CA 19-9 (control), indicating negligible nonspeciﬁc adsorption. The test line was still 
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observed at 5 U mL−1 of CA 19-9, which was the visual detection limit of CA 19-9 without 
instrumentation. All LFSBs showed the red control-line, which was a validation of the proper 
performance of the developed LFSBs. Quantitative detection was obtained by reading the intensity 
of the test line with the aid of a portable strip reader. The peak areas increased with the increasing 
intensity of the test lines, and thus correlated with increasing CA 19-9 concentrations. The 
resulting calibration curve (Figure 2.5. b) was plotted using the peak areas versus CA 19-9 
concentration to yield a linear dynamic range between 5 and 100 U mL-1 (R2=0.9927, y= 3.274x 
+ 22.615). The limit of detection (LOD) of the assay (S/N =3) was determined to be 5 U mL-1. 
Aside the low detection limit achieved, the developed LFSB showed good reproducibility. Six 
replicate tests were performed in the absence and presence of 30 U mL-1 of CA 19-9. The relative 
standard deviation of testing 0 U mL-1 and 30 U mL-1 were 2.1% and 3.2%, respectively (data not 
shown). The selectivity of the assay was studied by testing a series of probable interferences 
including CEA, human IgG and mammaglobin. As shown in Figure 2.6., a high response was 
observed when 30 U mL-1 CA 19-9 was tested, whereas negligible signals were obtained from 
other proteins with concentrations of 100 ng mL-1, indicating the excellent specificity of the assay.  
 
Figure 2.6. Selectivity of the developed GNP-based LFSB (concentration of CA 19-9 was 50 U 
mL-1; Mammaglobin, Human IgG and CEA were at 100 ng mL-1). 
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2.3.4. Detection of CA 19-9 in Healthy Human and Pancreatic Cancer Patient Plasma 
The developed assay was used to detect the concentrations of CA 19-9 in healthy human 
plasma and pancreatic cancer patient plasma samples. Six plasma samples each from healthy 
humans and pancreatic cancer patients were tested, and the results were validated with 
commercially available ELISA kit. Plasma samples from healthy humans were purchased from 
Golden West Biologicals, Inc. (Temecula, CA). Blood samples from pancreatic cancer patients 
were provided by Sanford Clinic. Plasma of pancreatic cancer patients were prepared by spinning 
the blood samples in an EP tube at 3000 g for 10 min and collecting the supernatant. Plasma (50 
µL) was diluted two-fold in a buffer containing PBS+2% BSA+1% CTAB before the test. Table 
2.1 shows the results from the developed QIA and ELISA. One can see that the analytical results 
of the QIA are in good agreement with the results obtained from ELISA, indicating that the QIA 
had good reliability for quantifying CA 19-9 concentrations in clinical samples. 
Table 2.1. Screening of plasma samples from healthy human and pancreatic cancer patients with 
the developed QIA and commercial ELISA kit. 
Plasma sample This assay (QIA) Commercial ELISA 
Healthy human plasma sample 1 12.67 ± 0.38 11.88 ± 0.75 
Healthy human plasma sample 2 30.76 ± 1.21 32.13 ± 1.62 
Healthy human plasma sample 3 0 0 
Healthy human plasma sample 4 24.56 ± 1.48 25.72 ± 2.11 
Healthy human plasma sample 5 10.51 ± 11.87 ± 0.92 
Healthy human plasma sample 6 21.92 ± 1.23 20.56 ± 1.01 
Pancreatic cancer patient sample 1 97.03 ± 0.67 95.72 ± 1.01 
Pancreatic cancer patient sample 2 113.49 ± 4.3 116.49 ± 3.45 
Pancreatic cancer patient sample 3 40.56 ± 2.12 42.26 ± 1.25 
Pancreatic cancer patient sample 4 0 0 
Pancreatic cancer patient sample 5 84.61 ± 2.56 86.45 ± 2.88 
Pancreatic cancer patient sample 6 97.03 ± 0.67 95.72 ± 1.01 
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2.4. Conclusion 
 A quantitative immunochromatographic assay was developed by using GNP-based lateral 
flow strip biosensor and a portable reader for the rapid and sensitive detection of CA 19-9. The 
assay was successfully applied to quantitate CA 19-9 concentrations in healthy human plasma and 
pancreatic cancer patient plasma samples. The detection limit of 5 U mL-1 achieved is sufficiently 
sensitive for clinical screening of CA 19-9 in plasma as the reported reference value of CA 19-9 
in healthy human plasma is 37 U mL-1.89 The developed assay provides a simple, rapid and 
inexpensive method to detect CA 19-9 in human plasma. The GNP-based lateral flow strip 
biosensor shows great promise for clinical application and biomedical screening, particularly in 
limited resource settings.  
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3. QUANTITATIVE GOLD NANOPARTICLE-BASED LATERAL FLOW STRIP 
BIOSENSOR FOR THE DETECTION OF CARCINOEMBRYONIC ANTIGEN (CEA) 
IN HUMAN PANCREATIC CYST FLUID 
3.1. Introduction 
Pancreatic cancer (PC), though the fourteenth most prevalent cancer, is the fourth leading 
cause of cancer related deaths in the United States.98 Much of the mortality from PC is the result 
of ineffective early diagnostic tests for PC screening. Traditionally PC has been diagnosed using 
imaging techniques like computed tomography, magnetic resonance imaging and angiography.99 
Other methods such as endoscopic ultrasound have also been used. The endoscopic ultrasound has 
the added advantage of being able to obtain tissue biopsies during examination, however, 
endoscopy is invasive and presents discomfort for patients. These diagnostic methods require the 
use of expensive equipment, skilled labor and expertise, and are therefore not feasible for routine 
screening.  
Biosensors present an alternative to the above-mentioned techniques. Biosensors are self-
contained devices that can screen biological samples and provide quantitative and semiquantitative 
analytical information using biorecognition elements linked to transducers.100,101 Biosensors for 
disease screening rely on biomarkers which are molecules whose upregulation or downregulation 
can be an indication of a diseased or abnormal medical condition. For pancreatic cancer, the two 
most common biomarkers used for screening are carcinoembryonic antigen (CEA) and 
carbohydrate antigen (CA 19-9). CEA was initially developed solely for pancreatic cancer and has 
become the most commonly used diagnostic marker for gastrointestinal cancers. Elevated CEA 
levels in pancreatic cancer patients prior to therapy has been linked to poor prognosis.98 
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Of interest, CEA levels in pancreatic cyst fluid has been useful in the differentiation of 
benign and malignant pancreatic lesions. CEA remains the most effective protein biomarker linked 
to malignant pancreatic cysts. In 2004, a study showed that cyst fluid CEA levels was superior to 
endoscopic ultrasound, cytology and other biomarkers such as CA 72-4, CA 125, CA 19-9, and 
CA 15-3 at differentiating between mucinous and non-mucinous pancreatic lesions.102 The 
diagnostic information obtained from cyst fluid analysis can determine whether patients are 
discharged, undergo further testing or scheduled for surgery.98,103 Cancerous pancreatic cysts are 
rare compared to the much more common benign pancreatic cyst.104 Pancreatic cancer once 
symptomatic, is invariably fatal. It is important that pancreatic cyst fluids are properly screened to 
give definitive diagnosis to avoid unnecessary surgery because the corrective surgery (pancreatic 
resection) is a major surgery that can result in complications and sometimes death.104 Cyst fluid 
samples are usually collected by either needle or endoscopic ultrasound biopsies. Cyst fluid 
biopsies generally result in samples a few microliters in volume depending on the size of the cyst. 
It is therefore of import to develop diagnostic assays that have very small sample volume 
requirements. 
CEA has been predominantly detected using enzyme-linked immunosorbent assays 
(ELISA).105 In ELISA, CEA is captured between capture antibodies pre-immobilized in a well 
plate, and detection antibodies labelled with enzymes such as horse radish peroxidase or alkaline 
phosphatase. Upon introduction of enzyme substrate, the substrate is converted to a colored 
complex whose absorbance can be measured for quantitative data. ELISA has seen wide 
application for detecting  proteins and is the most popular protein detection assay used for medical 
and diagnostic purposes. However, ELISA suffers setbacks such as the need for expensive plate 
readers, washers and requirement for trained expertise. Also, ELISA involves many washing steps 
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and long incubation hours. The assay time for ELISAs can vary from a few hours to as long as 2 
days which makes them unsuitable for point-of-care applications.105 Other methods like 
electrochemical assays that make use of nanoparticles for signal enhancement have also been 
reported for the detection of CEA.106,107 There has also been a label free electrochemical assay 
utilizing silver-molybdenum disulfide-graphene oxide nanocomposite scaffold as a means of 
signal amplification for highly sensitive CEA detection.108 CEA has also been detected using label-
free surface plasmon resonance (SPR) 109 as well as gold nanoparticle enhanced SPR110,111. Other 
immunoassays utilizing platforms like quartz crystal microbalance 112,113 and Raman spectroscopy 
114,115 have also been reported for CEA detection. These immunosensors offer low to acceptable 
sensitivity but suffer disadvantages of being expensive, requiring skilled expertise and having 
complex data processing requirements.  
Lateral flow strip biosensors (LFSB) offer a simple, rapid and inexpensive alternative to 
the traditional immunoassays. The simplicity of the LFSBs means their operation do not require 
expensive equipment nor trained technical personnel. In its simplest form, qualitative test results 
can be read with the naked eye for colorimetric LFSBs. Additionally, LFSBs have high specificity 
and good sensitivity, exhibit less or no interference due to inherent chromatographic separation, 
and have long term stability under non-refrigerated conditions.11 Their portability makes them 
prime candidates for point-of-care applications. The LFSB is a very versatile platform and has 
been applied widely in the medical, food and beverage, environmental monitoring industries for 
the detection of proteins 18,24,38,116, nucleic acids 23,25,28, cells 15, toxins 63,117, bacteria 117,118, and 
other small molecules 11,17. For the transduction of target molecules capture into measurable 
signals, various nanoparticles like GNP 15,72,119, carbon nanotubes 25, fluorescent nanoparticles 
23,120,121, magnetized carbon nanotubes 26,27, GNP-coated silica nanorods 24,45 and liposomes 28,116 
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have been used with varying degrees of sensitivity. However, GNPs are the gold standard for 
lateral flow strip biosensors. GNPs have intense red color because of their surface plasmon 
property that makes them ideal for colorimetric LFSB applications. In addition, GNPs are stable, 
simple and inexpensive to prepare, and easy to conjugate to biorecognition elements. GNPs have 
been used for the detection of various targets with good sensitivity.11,19,72 We previously reported 
a GNP-based lateral flow strip biosensor for the detection of CA 19-9 in human plasma samples 
that showed good performance and was able to distinguish between of healthy and pancreatic 
cancer patient samples.119  
This work reports a simple, rapid and sensitive GNP-based lateral flow strip biosensor for 
the detection of CEA protein in pancreatic cyst fluid. The developed biosensor detected CEA in a 
sandwich type immunoassay by capturing target CEA in-between a capture antibody immobilized 
on a solid support (nitrocellulose membrane) and a GNP-linked detection antibody. The CEA 
dependent accumulation of GNPs on the test zone gave a red colored band that gave qualitative 
data via visual observation or quantitative data by reading test line intensities with a portable strip 
reader. The developed assay had the added advantage of requiring low sample volumes which 
makes it ideal for the screening of pancreatic cyst fluid biopsies. The developed GNP-based LFSB 
was sufficiently sensitive with a detection limit of 2 ng mL-1 without any form of signal 
amplification. The assay was successfully applied for the detection of CEA in pancreatic cyst fluid, 
and positively distinguished between mucinous and non-malignant pancreatic cysts. The 
developed assay shows great potential for the clinical screening of CEA in limited resource 
settings.  
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3.2. Experimental Section 
3.2.1. Apparatus 
The Biojet BJQ 3000 dispenser, Clamshell Laminator and Guillotine cutting module CM 
4000 used for the assembling of the LFSB were bought from Biodot LTD (Irvine, CA, USA). 
Strips were quantitatively read with a portable strip reader (DT2032) acquired from Shanghai 
Goldbio Tech. Co., LTD (Shanghai, China). Strip images were captured with a S7 smart phone by 
Samsung Electronics (Seoul, South Korea). 
3.2.2. Reagents and Materials  
Gold (III) chloride (HAuCl2), phosphate buffered saline (0.01 M PBS, pH 7.4), trizma 
hydrochloride buffer solution (Tris-HCl, 1.0 M, pH 8.0), tween 20, triton X-100, bovine serum 
albumin (BSA), sucrose, sodium chloride (NaCl), magnesium chloride (MgCl2) and sodium 
phosphate tribasic deodecahydrate (Na3PO4.12H2O) were purchased from Sigma–Aldrich (St. 
Louis, MO, USA) and were used without further purification. Native CA 19-9 (30-AC14), native 
CEA protein (30-1819) and anti-CEA antibodies (10-C10F and 10-C10G) were purchased from 
Fitzgerald Inc. Goat anti-mouse immunoglobulin G (IgG), trypsin and human IgG were purchased 
from Thermofisher Scientific (Waltham, MA, USA). Recombinant C4b-binding protein alpha 
chain (C4BP- α) was purchased from MyBioSource Inc. (San Diego, CA, USA). Human 
mammaglobin was bought from Creative BioMart (Shirley, NY, USA). Glass fibers 
(GFCP000800), cellulose fiber (CFSP001700), and nitrocellulose membranes (HFC090MC100, 
HFC135MC100, HFC180MC100) were purchased from Sigma–Aldrich (St. Louis, MO, USA) for 
biosensor fabrication. Human pancreatic cyst fluid samples were obtained from the University of 
Pittsburg Medical Center. All reagents were analytical grade. All solutions used in the study were 
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prepared in ultrapure (≥18M Ω) water from Millipore Milli-Q water purification system (Billerica, 
MA, USA). 
3.2.3. Preparation of the GNP and GNP-Anti-CEA Conjugate 
GNPs with diameters 13nm ± 3.5 were prepared by the citrate reduction method as 
previously described.97 Glassware was washed with detergent and thoroughly rinsed with water. 
The glass vessels were then soaked in aqua regia (3:1; HCl:HNO3) overnight and rinsed with 
copious amounts of water. Fifty microliters (50uL) of 50% w/v HAuCl4 was mixed with ultrapure 
water in a glass vessel. The mixture was brought to boil with constant stirring. Sodium citrate was 
added, and the mixture was boiled with constant stirring until the color of the solution changed to 
the characteristic red color of GNPs. The solution was boiled for 10 additional minutes. The 
prepared GNPs were then cooled to room temperature and stored at 4°C until used. 
One milliliter (1mL) of 5-fold concentrated GNPs were prepared by spinning prepared 
GNPs at 12,400 rpm for 15 mins. GNP pellets were collected and resuspended in water at pH=9. 
Forty micrograms (40ug) of anti-CEA Ab G (10-C10G) was added and incubated at room 
temperature for 2 hours with gentle shaking. BSA solution (10% w/v) was subsequently added to 
a final concentration of 1% and mixture was further incubated for 1hour. Prepared GNP anti-CEA 
conjugates were washed with 1% BSA solution by spinning at 12,400 rpm for 15 mins. The 
washing step was repeated two more times. The conjugates were then suspended in 1.0 mL eluent 
buffer (20 mM Na3PO4·12H2O, 5% BSA, 10% sucrose, and 0.25% Tween-20). The conjugates 
were stored at 4°C until used. 
3.2.4. Preparation of GNP-Based LFSB for CEA Detection 
The setup for the GNP-based LFSB for CEA detection was as shown in Figure 3.1. The 
biosensor consisted of three major components (conjugate pad, nitrocellulose membrane and 
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absorption pad) all assembled on a sticky nonporous plastic backing card. The conjugate pad was 
a glassy fiber onto which the conjugate was dispensed prior to assay runs. The glassy material was 
porous to enable the holding of adequate amounts of conjugates. The conjugate pad was also 
capable of releasing the conjugates when assay was run. The nitrocellulose membrane supported 
the test and control line biorecognition elements. Anti-CEA Ab F (10-C10F) and goat anti-mouse 
IgG at concentrations of 1 mg mL-1 were dispensed as test and control lines respectively. After 
dispensing, the membrane was dried at 37°C for 1hour. Membranes were stored at 4°C until used. 
The absorption pad was a cellulose pad that wicked the assay fluids and provided capillary force 
as assay was run. All three components were assembled on the sticky backing layer and secured 
using the Clamshell Laminator. The components overlapped by at least 2mm to ensure continuous 
fluid flow. The assembled biosensor was cut into 3mm width strips with the guillotine cutter. 
Prepared biosensors were kept at 4°C until used. 
 
Figure 3.1. Scheme of the developed GNP-based Lateral Flow Strip Biosensor for the detection 
of CEA. 
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3.2.5. Assay Procedure 
GNP-anti CEA Ab G conjugate was dispensed on the conjugate pad and allowed to air dry 
for 5 mins prior to running the assay. 100 µL of native CEA protein dissolved in running buffer 
(PBS + 1%Tween + 1% BSA + 1% PVP) was applied to the conjugate pad. The solution run 
through the strip for 20 mins. The GNP-based LFSB was then washed with 100 µL of running 
buffer. The washing step helped remove any nonspecifically adsorbed GNP-anti CEA conjugates 
on the test zone. The biosensor could be visually observed for qualitative data within 30 mins. The 
test and control line intensities were read with the portable strip reader to obtain quantitative data. 
To test the GNP-based LFSB’s performance on real samples, pancreatic cyst fluid samples were 
diluted down to 10% v/v in running buffer with final buffer composition (PBST + 1% BSA + 1% 
PVP). Assay procedure and acquisition of test and control line intensities were the same as 
described earlier. 
3.3. Results and Discussion  
3.3.1. Working Principle of GNP-Based LFSB for CEA Detection 
The GNP-based LFSB detected target CEA following a sandwich type immunoassay 
format as depicted in Figure 3.2. Anti-CEA Ab F and goat anti-mouse IgG were pre-immobilized 
on the nitrocellulose membrane as test and control lines. Anti- CEA Ab G served as the detection 
antibody and thus used for the preparation of the GNP-conjugate. The GNP-anti-CEA Ab G 
conjugate was dispensed onto the conjugate pad. When target was applied to the conjugate pad, 
the CEA moved by capillary action and underwent an immunoreaction with the anti-CEA Ab G 
of the GNP-conjugate to form an immunocomplex (GNP-anti-CEA Ab G-CEA). The 
immunocomplex moved further onto the nitrocellulose membrane and the CEA component 
underwent a second immunoreaction with the test line anti-CEA Ab F. The immunocomplex was 
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thus immobilized on the test line in presence of CEA resulting in a characteristic red colored line 
due to the GNP component. Excess GNP-anti-CEA Ab G conjugate moved further to the control 
line and were captured by the goat-anti mouse IgG resulting in a red second band on the control 
line. Thus, in the presence of target, two red bands were observable on the GNP-based LFSB 
(Figure 3.2. a). No immunoreaction occurred on test line in the absence of target CEA, however, 
the GNP-anti-CEA conjugates were captured on the control line resulting in a single red band 
(Figure 3.2. b). The test strips were examined with the naked eye for qualitative information. For 
quantitative data, test and control line intensities were read with the portable strip reader connected 
to a computer. The strip reader captured images of the test and control lines and converted their 
pixel intensities into gaussian peaks. The area under the curves gave indication of the number of 
GNPs immobilized on the test line which was directly proportional to the CEA levels present in 
test samples. 
 
Figure 3.2. Working Principle of the developed GNP-based LFSB for CEA detection (a) Assay in 
the presence of target CEA (b) assay in the absence of CEA. 
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3.3.2. Optimization of Experimental Parameters 
The performance of the GNP-based LFSB relied on the interplay of several assay 
parameters (type of nitrocellulose membrane, dispense times of test line, running buffer 
composition, antibody concentration for conjugate preparation and the volume of conjugate used 
per test run). It was necessary to optimize these experimental conditions to attain the best 
sensitivity and specificity of the developed assay.  
The first line of optimization was selecting  the type of nitrocellulose membrane on which 
the test and control line antibodies were dispensed. Three membranes (HF090MC100, 
HF135MC100, HF180MC100) with flow rates of 90, 135 and 180 sec 4cm-1 membrane were tested 
for their performance on the GNP-based LFSB and their signal-to-noise (S/N) ratios compared 
(Figure 3.3. a). The membrane flow rate determined the time frame of exposure for the test and 
control line immunoreactions. As seen from Figure 3.3. a, the 90sec membrane showed lowered 
S/N ratio. This was ascribed to the faster flow rate of the 90 sec membrane which reduced the 
exposure time for the test and control line immunoreactions. This resulted in lowered test line 
intensities which lowered the S/N ratio. The 180sec membrane which had the slowest flow rate 
showed the lowest S/N ratio. The slow flow rate increased the exposure time for the test zone 
immunoreaction. This resulted in increased nonspecific interactions which increased background 
signals and resulted in the observed low S/N ratio. The best S/N ratio was observed with the 135sec 
membrane which had the optimal flow rate to maximize the S/N ratios. 
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Figure 3.3. (a) Effect of nitrocellulose membrane type on the S/N ratio of the assay (b) Effect of 
the dispense times of test line anti-CEA Ab F on the S/N ratio of the assay (c) Effect of buffer 
composition on the performance of the assay. 
The dispense times of the test line antibody was the next parameter to be optimized. The 
antibody concentration on the test line significantly affected the performance of the developed 
assay. The anti-CEA Ab F was dispensed varying number of times (1, 2, 3, 4 and 5) on the 
nitrocellulose membrane and their S/N ratios compared (Figure 3.3. b). Lower concentrations of 
antibodies at 1 and 2 times dispense cycles resulted in lowered test line intensities and thence lower 
S/N ratios. At higher dispensed cycles (4 and 5x) there was lowering of S/N ratios as increased 
antibody concentration on test line led to increased nonspecific interaction. The highest S/N ratio 
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was observed at 3x dispense cycles which had the ideal antibody coverage. 3x dispensing of the 
test line antibody and was chosen for further development of the biosensor. 
The immunoreactions in the assay occurred in buffer solutions and the strength of these 
interactions were affected by the buffer compositions. Different buffered solutions including PBS 
+ 1% BSA, PBS + 1%BSA + 1%PVP, PBST + 1% BSA, PBST + 1%BSA + 1%PVP, Tris-HCl + 
1% BSA and Tris-HCl + 1% BSA + 1%PVP were tested for their performance on the GNP-based 
LFSB and their S/N ratios compared (Figure 3.3. c). The highest S/N ratio was measured in PBST 
+ 1%BSA + 1%PVP, which was then chosen for further development of the LFSB. 
The amount of anti-CEA Ab G coated on the surface of the GNPs was the next parameter 
to be optimized. To 1mL of 5-fold concentrated GNPs, varying amounts (10, 20, 30, 40, and 50 
µg) of anti-CEA Ab G was added for the preparation of the conjugate. The prepared GNP- anti-
CEA Ab G conjugates were tested for their performance on the LFSB and their S/N ratios 
compared (Figure 3.4. a). At 10 µg of anti-CEA Ab G, the lowest S/N ratio was observed. This 
was attributed to insufficient coverage of the GNP surface and lowered sandwich formation 
efficiency in the assay, which resulted in low test line intensities. The highest S/N ratios were 
observed when 20 µg of anti-CEA Ab was used for conjugate preparation. Beyond 20 µg there 
was a steady reduction in S/N ratios. The lowered performance was ascribed to steric hindrance 
due to antibody over-crowding on the surface of the GNPs. The over-crowding hindered the 
accessibility of the target CEA for binding to the of anti-CEA Ab G on the GNPs. 20 µg anti-CEA 
Ab G was therefore chosen for further preparation of conjugates for development of the GNP-
based LFSB. 
The final parameter optimized was the amount of GNP-anti-CEA Ab G conjugate 
dispensed on the conjugate pad. Varying volumes (2, 4, 6 and 8 µL) of conjugate were dispensed 
 45 
on the conjugate pad and their performance on the LFSB compared as shown in Figure 3.4. b. 
Having low volumes of conjugates (2 and 4µL) dispensed resulted in lowered test line intensities 
and thus lowered S/N ratios. The S/N ratio peaked at 6 µL of conjugate, beyond which there was 
lowered S/N ratios. At higher volume beyond 6 µL conjugate, there was increased nonspecific 
interactions which led to high background signals and thus the observed lower S/N ratios. 6 µL of 
GNP- anti-CEA Ab G conjugate was therefore used for further testing. 
 
Figure 3.4. (a) Effect of the amount of anti-CEA Ab F used for conjugate preparation on the S/N 
ratio of the assay (b) Effect of conjugate volume on the S/N ratio of the assay. 
3.3.3. Analytical Performance 
Under optimized conditions (135sec membrane, 3x dispense cycles of the test line, PBST 
+ 1%BSA + 1%PVP running buffer, 20 µg anti-CEA Ab G for conjugate preparation, and 6 µL 
conjugate per test) CEA with concentrations ranging from 0 to100 ng mL-1 was tested on the 
developed GNP-based LFSB. Photo images of the strips were taken as displayed in Figure 3.5. a. 
The intensity of the test line increased with increasing concentration of target CEA. In the absence 
of CEA, no visible test line band was observable. This proved that after the optimization process 
there was negligible nonspecific interactions. For quantitative data the test line intensities were 
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measured with the portable strip reader and peak intensities were plotted against corresponding 
CEA concentrations to obtain a calibration curve (Figure 3.5. b). The calibration curve had good 
linearity with R² = 0.9937. The equation of the curve was y = 7.3807x + 22.079, where y was peak 
intensity and x was the concentration of CEA (ng mL-1). The assay showed good performance with 
linear dynamic range from 3 to 100 ng mL-1. The detection limit of the assay was determined to 
be 2 ng mL-1 (S/N=3).  
 
Figure 3.5. (a) Photo images of assay in the presence of varying amounts (0 – 100 ng mL-1) of 
CEA (b) Corresponding calibration curve. Each data point corresponds to the averaged test line 
intensities from three replicate tests. 
The developed assay also showed good reproducibility. Six replicates of CEA at 
concentrations of 5 and 50ng mL-1 were tested  with the GNP-based LFSB and the relative standard 
deviations were 5.23% and 7.15% respectively (data not shown). To assess the selectivity of the 
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developed assay, CA-19-9 at concentration of 100U mL-1 and various proteins like mammaglobin, 
trypsin, Human IgG and C4BP-alpha at concentrations of 100ng mL-1 were tested and their signals 
compared to CEA protein at 30ng mL-1 (Figure 3.6.). As observed, CEA at 30ng mL-1 showed a 
much higher test line peak intensity compared to the other targets. The test line intensities from 
the other proteins and CA19-9 were akin to the signal of the blank, indicating excellent selectivity 
of the developed biosensor. 
 
Figure 3.6. Selectivity of the developed GNP-based lateral flow strip biosensor. Assay in the 
presence of CEA (30 ng mL-1); Mammaglobin, Trypsin, C4BP-alpha and Human IgG at 
concentrations of 100 ng mL-1; CA 19-9 (100 U mL-1); and blank (running buffer). 
3.3.4. Detection of CEA in Human Pancreatic Cyst Fluid 
To access the feasibility of the developed GNP-based LFSB for clinical diagnostics, CEA 
concentrations in pancreatic cyst fluid samples were measured using the developed sensor. The 
pancreatic cyst fluid samples were obtained from the University of Pittsburg Medical Center. 
There were 7 samples in total; six pancreatic cancer patient cyst fluid samples (PC 1 to PC 6) and 
one non-malignant pancreatic cyst sample (NM). 
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Figure 3.7. Screening of human pancreatic cyst fluid with developed GNP-based lateral flow strip 
biosensor. Pancreatic cancer patient cyst fluid (PC1 to PC6) and non-malignant pancreatic cyst 
fluid (NM). 
From Figure 3.7 it is observed that the pancreatic cancer cyst fluid samples showed 
significantly higher CEA levels compared to the non-malignant cyst fluid sample. The reference 
CEA value employed was 192 ng mL-1 as previously reported.102 All six pancreatic cancer patient 
cyst fluid samples showed levels above the reference value. The developed biosensor showed good 
performance in the pancreatic cyst fluid and was able to distinguish mucinous cyst from non-
malignant pancreatic cysts. The developed GNP-based LFSB exhibits great potential for the 
clinical screening of CEA levels in pancreatic cyst fluid samples. 
3.4. Conclusion 
A GNP-based lateral flow strip biosensor was developed for the rapid and sensitive 
detection of CEA. Quantitative data was collected by reading test line intensities with a portable 
strip reader. The developed assay was successfully used to measure CEA levels in pancreatic 
cancer cyst fluids, and to distinguish mucinous pancreatic cyst from non-malignant pancreatic cyst. 
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The detection limit if the assay was determined to be 2 ng mL-1 (S/N ratio=3) which was well 
below the CEA reference value of 192 ng mL-1 in pancreatic cyst fluid. The developed GNP-based 
LFSB presents a simple, rapid and low-cost assay for the quantitative measurement of CEA levels 
in pancreatic cyst fluids. The developed assay has the potential to be applied clinically for 
diagnostics particularly in limited resource settings. 
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4. MULTI-WALLED CARBON NANOTUBE-BASED LATERAL FLOW BIOSENSOR 
FOR ULTRASENSITIVE DETECTION OF PROTEINS IN HUMAN PLASMA 
4.1. Introduction 
The detection of proteins is an area of interest in various fields of study. Protein levels have 
served as indicators of quality and safety in the food and beverage industries. In the medical and 
veterinarian fields various ailments can be diagnosed by detecting protein biomarkers associated 
with the diseased conditions. Traditional protein assays which involve reaction of proteins with 
various chemicals to give colored complexes only afford information about bulk protein content 
and amino acid composition.6,122–125 Based on their sequences, proteins with aromatic ringed 
amino acids have characteristic absorbance at 280 nm which have been utilized for protein 
quantitation. Methods like agarose and polyacrylamide electrophoresis which separate out proteins 
have also been used for protein detection.125,126 These methods generally involve multiple steps 
and lack sufficient selectivity and sensitivity. There is therefore the need for assays that provide 
more selective and sensitive protein detection. 
Immunoassays utilize antibodies to capture target analytes and provide a selective method 
for detecting proteins. Immunoassays have gained a lot of attention for protein detection in medical 
diagnosis, quality control in the food industry as well as in environmental analysis.127–129 The most 
commonly used immunoassay approach for the detection of proteins is the Enzyme-Linked 
Immunosorbent Assay (ELISA). ELISAs have gained increased use in medical laboratories as well 
as external quality control and proficiency testing organizations.130 Traditional ELISA assays 
utilize antibodies labelled with enzymes such as horse-radish peroxidase which catalyzes substrate 
conversion to colored complexes. The intensities of the enzymatic product which is target protein 
dependent can be measured by spectroscopic techniques to obtain quantitative data. ELISAs  offer 
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acceptable selectivity and sensitivity, however, tedious test procedures, prolonged assay time and 
requirement of highly trained personnel which limit its applications for point-of-care and in-field 
detection.131 Although the introduction of automated ELISA instrument has overcome some of the 
disadvantages of the traditional ELISA, the cost is still of significant concern.18 
Immunosensors are highly versatile and can be linked with various transducers based on 
electrochemical, optical and piezoelectric technologies.125,132 Electrochemical immunosensors that 
utilize enzyme labels such as horse-radish peroxidase, glucose oxidase, acetylcholinesterase, 
tyrosine etc. have been reviewed .133 The enzymatic products with electrochemical activities give 
measurable electrical signals. Other electrochemical assays measuring change in electrical 
conductivity upon protein capture have also been reported.134 Nanoparticles like gold  and 
platinum nanoparticles, and quantum dots (QDs) have been used as labels to improve the 
sensitivity of electrochemical assays.135–137 In spite of their high sensitivity, electrochemical assays 
can suffer drawbacks of  having low reproducibility, and fragility of enzyme based systems which 
can limit their application for biomarker screening. 
Lateral flow biosensors (LFB) which are paper-based sensors circumvent the shortcomings 
of the aforementioned immunoassays. In recent years, LFBs have attracted considerable interest 
because they offer simple, rapid, portable and low-cost detection of analyte.11,18,119,138,139 Lateral 
flow assays are therefore ideal for POC applications. LFBs are highly versatile and have been used 
in a variety of sample matrices across different industries.18,24,25,45,90,96,119,140 Various nanoparticles 
have been utilized as labels for the detection of analyte on lateral flow strips.25,27,45,141–143 Gold 
nanoparticles are the gold standard for the preparation of LFBs and have been developed for the 
detection of various targets.18,19,119,144 GNPs are usually used as labels for the generation of visible 
signal because of their surface plasmon property that gives them a size dependent red color.21,145 
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However, because of the limited surface area of the GNPs, the assays often suffer from low 
sensitivity. Innovative signal amplification protocols have been reported using enzymes18, 
catalytic nanoparticles146 and dual conjugates147. These amplification strategies improve the 
sensitivity of the LFBs, however, because of the low concentration of certain protein biomarkers 
in physiological fluids, there is the need for more sensitive LFBs.  
Since their discovery in 1991148, carbon nanotubes (CNTs) have attracted significant 
attention because of their unique properties.149–151 CNTs provide a large surface area for 
biomolecular conjugation (Zhang et. al., 2011).152 They therefore have the potential to be used in 
place of GNPs as labels in LFBs. Based on this premise, our group previously published a CNT-
based lateral flow assay for the detection of DNA which showed improvement over the 
conventional GNP-based LFB for DNA detection.25 Abera and Choi reported an electrochemical 
detection of human IgG based on changes in resistance of the test zone of LFB upon CNT 
accumulation. This electrochemical assay suffered low sensitivity with a detection limit of 20 µg 
mL-1.153 Meng and colleagues reported a cotton string assay that utilized CNTs for the visual 
detection of ferroprotein. The cotton strip assay achieved an improved LOD of 50 ng mL-1.154 
Subsequently, there has been a report of a GNP-decorated carbon nanotube nanocomposite-based 
cotton string assay for the detection of Squamous cell carcinoma antigen with detection limit 3ng 
mL-1.155 The cotton string assay was unable to improve on the detection limits of the GNP-based 
LFBs. There is still the need for more sensitive LFBs for clinical diagnosis as some medically 
important proteins are present at very low concentrations. 
In this study, a MWCNT-based LFB is introduced for the ultrasensitive detection of 
proteins in human plasma. The assay utilized the unique properties (color, high aspect ratio and 
ease of surface modification) of MWCNTs to aid the highly sensitive detection of proteins. Rabbit 
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IgG was adopted as a model target to demonstrate the proof-of-concept. Rabbit IgG was captured 
in a sandwich assay between capture antibody immobilized on the test zone and detection antibody 
conjugated to the shortened multi-walled CNTs. Accumulation of CNTs on the test line gave a 
black colored line which was detectable with the naked eye at 5 pg mL-1. A detection limit of 1.32 
pg mL-1 was achieved after optimization of experimental parameters. The detection limit of the 
developed assay was over 3 orders lower than that of previous GNP-based LFB. The clinical 
diagnostic utility of the developed MWCNT-based LFB was successfully demonstrated by 
detecting rabbit IgG  spiked into human plasma samples. The promising properties of the approach 
are reported in the following sections. 
4.2. Experimental Section 
4.2.1. Apparatus 
The Airjet AJQ 3000 dispenser, Biojet BJQ 3000 dispenser, Clamshell Laminator, and 
Guillotine Cutting module CM 4000 were purchased from Biodot LTD (Irvine, CA, USA), 
Quantitative data was collected using a portable test strip reader (DT2032) purchased from 
Shanghai Goldbio Tech. Co., LTD (Shanghai, China). Fourier-transformation infrared (FTIR) 
spectral readings were performed on Nicolet iS10 FTIR spectrometer manufactured by Thermo 
Fisher Scientific, Inc. (Rockford, IL, USA). Absorbance measurements were performed on the 
Nanodrop purchased from Thermo Fisher Scientific, Inc. (Rockford, IL, USA). 
4.2.2. Reagents and Materials 
Carboxylated multi-walled carbon nanotubes (carboxyl-MWCNT) (purity > 95 wt%) was 
purchased from Sun NanoTech (Nanchang, Jiangxi Province, China). Rabbit immunoglobulin 
(IgG), Goat anti-rabbit IgG (GaR IgG), donkey anti-goat IgG, human-IgG and thrombin were 
obtained from Thermo Fisher Scientific, Inc. (Rockford, IL, USA). Carcinoembryonic antigen 
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(CEA) and carbohydrate antigen (CA 19-9) were obtained from Fitzgerald Industries International 
(Acton, MA, USA). Human mammaglobin was purchased from Creative BioMart (Shirley, NY, 
USA). 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) , N-
hydroxysulfosuccinimide (sulfo-NHS), 2-(4-Morpholino) ethanesulfonic acid (MES), tween 20, 
triton X-100, bovine serum albumin (BSA), sucrose, polyvinylpyrrolidone (PVP), phosphate 
buffer saline (0.01 M PBS, pH 7.4) and trizma hydrochloride buffer solution (Tris-HCl, 1.0 M, pH 
8.0) were purchased from Sigma–Aldrich (St. Louis, MO, USA) and were used without further 
purification. Glass fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), 
nitrocellulose membranes (HFC090MC100, HFC180MC100, HFC240MC100) were purchased 
from Millipore (Billerica, MA). Human plasma were purchased from Golden West Bio (Temecula, 
CA, USA). All the chemicals used in this study were analytical reagent grade. Solutions used were 
prepared with ultrapure (≥18M Ω) water from Millipore Milli-Q water purification system 
(Billerica, MA, USA). 
4.2.3. Preparation of MWCNT-Antibody Conjugates 
The carboxyl-MWCNTs were treated with mixed acid solution (HNO3:H2SO4, 1:3) under 
ultrasonication for 3 hours to shorten them. The acid treatment has been reported to shorten the 
lengths and introduce carboxyl groups onto the surface of CNTs.156 The shortened carboxyl-
MWCNTs was washed by centrifugation with ultrapure water until the pH of supernatant was 
neutral. Shortened carboxyl-MWCNT (0.5 mg) was mixed with EDC (9.6 mg) and sulfo-NHS 
(5.43 mg) in 1mL MES buffer (0.1 M, pH 6.0) to activate the carboxyl groups. The mixture was 
incubated at room temperature (RT) for 15 min followed by washing by centrifugation (10,000 
rpm for 5min). The supernatant was removed, and the pellet was resuspended in PBS buffer. The 
 55 
washing step was repeated 3 times. The resulting pellet was resuspended in PBS and GaR IgG was 
added to a final volume of 1.0 mL. The mixture was then incubated overnight at 4°C with gentle 
shaking. This mixture was then centrifuged at 5,000 rpm for 5 min. The supernatant was removed, 
and pellet was resuspended in PBS. The supernatant was monitored at each wash step using the 
nanodrop to determine concentration of excess GaR IgG. The conjugate was washed till no protein 
absorbance was measurable in the supernatant. Based on the amount unbound GaR in the 
supernatant relative to initial GaR concentration it was calculated that 1.0 mg of CNTs binds 18.83 
± 0.5 µg GaR IgG. After the final wash the GaR IgG-CNT conjugate was resuspended in 1.0 mL 
eluent buffer (20 mM Na3PO4·12H2O, 5% BSA, 10% sucrose, and 0.25% Tween-20). The 
conjugate was stored at 4°C until used. 
4.2.4. Preparation of the MWCNT-Based LFB 
The CNT-based LFB consisted of a conjugate pad, nitrocellulose membrane and absorbent 
pad as shown in Figure 4.1. The conjugate pad (21 mm ×30 cm) was a porous glassy fiber 
membrane on which the conjugate was dropped. Desired volumes of GaR IgG and Donkey anti-
goat IgG solutions were dispensed on the nitrocellulose membrane (25 mm×30 cm) as test and 
control zones respectively, using the Biojet BJQ 3000 dispenser. The distance between the test and 
control lines was about 3 mm. After dispensing, the membrane was dried at 37°C for 1 hr and 
stored at 4°C. All three components were assembled on an adhesive plastic backing layer (60 
mm×30 cm) using the clamshell laminator. Each component was overlapped by at least 2 mm to 
ensure that the test solution could migrate through the strip during the assay. The assembly was 
cut with the Guillotine cutting module CM 4000 into 3 mm width strips. The prepared strips were 
stored at 4°C until used. 
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Figure 4.1. Configuration of the MWCNT-based LFB for protein detection. 
4.2.5. Assay Procedure 
GaR IgG-MWCNT (4 μL) was dropped on the conjugate pad and allowed to air dry for 
5mins. One hundred microliters (100 μL) of sample Rabbit IgG solution prepared in running buffer 
(PBS 1% BSA, 1% PVP) was applied to the MWCNT-LFB. The solution travelled along the 
biosensor from the conjugate pad towards the absorption pad. After 20 mins, 100 μL of running 
buffer was added to wash the strip. The washing step was to clear up any nonspecifically adsorbed 
conjugates on the nitrocellulose membrane to reduce background signals. The test and control lines 
could be visually evaluated within 20 mins. For quantitative measurements, the optical intensity 
of the test and control lines were read with a portable strip reader. To test the strip performance in 
plasma, 10% human plasma spiked with different concentrations of Rabbit IgG were prepared in 
PBS containing 1% BSA and 1% PVP. The test procedure and quantitative data acquisition were 
the same as described above. 
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4.3. Results and Discussion 
4.3.1. Characterization of the Shortened MWCNTs  
Figure 4.2. a and b show the typical transmission electron microscopy images of the 
MWCNTs before and after acid treatment. One can see the average length of the unshortened 
MWCNT is around 1 to 3 µm (Figure 4.2. a), and the length of the shortened MWCNT is around 
200 to 600 nm (Figure 4.2. b). The length of MWCNT was reduced significantly after acid 
treatment.  
 
Figure 4.2. (a) TEM image of unshortened MWCNTs (b) TEM image of shortened MWCNTs; 
(c) FTIR spectra of MWCNT before and after acid treatment. 
The shortened MWCNTs were analyzed by FTIR to assess the surface functionality before 
and after acid treatment. Using equal mass (0.2 mg) of shortened and unshortened MWCNTs, the 
FTIR spectra showed increased band intensities for O-H stretch, and C=O after acid treatment as 
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shown in Figure 4.2. c. This was an indication of increased carboxylation of the MWCNT after 
the acid treatment. 
4.3.2. Principle of MWCNT-Based LFB for Protein Detection 
The working principle of the MWCNT-based LFB is illustrated in Figure 4.3. Rabbit IgG 
and polyclonal GaR IgG were used as a model to demonstrate the proof-of-concept. Polyclonal 
GaR IgG interacted with the rabbit IgG in more than one site and was used as both capture and 
detection antibody to prepare the LFB. Typically, GaR IgG-MWCNT conjugate solution with a 
desired volume was dropped on the conjugate pad and allowed to air-dry. Sample solution 
containing rabbit IgG was applied to the conjugate pad (Figure 4.3. a). The solution migrated by 
capillary action through the strip. Target first interacted with the GaR IgG-MWCNT conjugate 
and an immunoreaction occurred between the rabbit IgG and the GaR IgG on the MWCNT surface 
(Figure 4.3. b). This formed a rabbit IgG-GaR IgG-MWCNT complex which continued to migrate 
along the test strip. Upon reaching the test zone, pre-immobilized GaR IgG reacted with the rabbit 
IgG of the complex in a second immunoreaction event. A characteristic black band was observed 
on the test zone because of the accumulation of MWCNTs (Figure 4.3. c). The intensity of the 
black band on test zone was dependent on the concentration of target rabbit IgG. Once the solution 
reached the control zone, the excess GaR IgG-MWCNT conjugates were captured on the control 
zone by the secondary antibody (Donkey anti-goat IgG). Thus, in the presence of target two black 
bands were visually observed for qualitative data (Figure 4.3. c). 
In the absence of the target IgG, one black band was observed due to the capture of the 
GaR IgG-MWCNT conjugate on the control zone by the pre-immobilized donkey anti-goat IgG 
(Figure 4.3. d). In this case, the black band of the control zone showed that the LFB was in good 
working condition. There was no black band on the test zone in this case because the rabbit IgG 
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(which was absent) was required for the formation of sandwich structure on the test zone. 
Quantitative data was obtained by reading the test band intensities using the portable strip reader. 
 
Figure 4.3. Working Principle of the developed MWCNT- based LFB. (a) Sample introduction 
(b) Immunoreaction between target and GaR-MWCNT conjugate (c) Capture of rabbit IgG-GaR-
MWCNT complex on test line and the excess of GaR-MWCNT conjugate on the control line 
(d) Assay in the absence of target rabbit IgG. 
To confirm the proposed signal improvement obtainable by replacing GNPs with 
MWCNTs as labels for protein detection on the LFB, sample solutions with three different 
concentrations of rabbit IgG were tested on the MWCNT-based LFB and the traditional GNP-
based LFB. Figure 4.4 shows the photo images of LFBs after testing 5, 1 and 0 ng mL-1 rabbit IgG 
in sample solutions. 
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Figure 4.4. Photo images of the GNP-based LFBs (left) and the MWCNT based LFBs (right) with 
varied concentration of Rabbit IgG: (a.) 5 ng mL–1 (b.) 1.0 ng mL–1 (c.) 0 ng mL–1. 
In the presence of 5 ng mL-1 target, the MWCNT-based LFB shows a very intense black 
band while the GNP-based LFB shows a significantly less intense test band (Figure 4.4. a). For 
the 1 ng mL-1 rabbit IgG test, again, the MWCNT-based LFB showed a prominent black band on 
the test zone and a barely visible red band was observed on the GNP-based LFB (Figure 4.4. b). 
In the absence of target there was no visible test zone band on either LFBs (Figure 4.4. c). The 
above results indicate that the use of MWCNT label significantly increased the signal of the test 
band on the LFB. The improved sensitivity achieved by the CNTs is mainly due to their large 
aspect ratio which enabled immobilization of increased amounts of antibodies that improved the 
capture efficiency of target rabbit IgG. Also, the intense black color of the MWCNTs  increased 
their contrast against the white nitrocellulose membrane which supported the test and control 
zones.  
a.
b.
c.
Control line
Test line
Control line
Test line
Control line
Test line
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4.3.3. Optimization of Experimental Parameters 
To attain the highest sensitivity of detection various assay parameters including type of 
nitrocellulose membrane, dispense times of test line, buffer conditions, conjugates were optimized. 
Firstly, the nitrocellulose membrane on which the test line and control lines were dispensed was 
optimization. The performance of three membranes (HF090MC100, HF180MC100 and 
HF240MC100 with flow rates of 90secs, 180secs and 240secs per 4 cm respectively as reported 
by the manufacturer) were assessed for their performance on the MWCNT-LFB. The flow rate on 
the nitrocellulose membrane dictated the time frame for the immunoreactions at the test and control 
lines. As shown in Figure 4.5. a, the 180sec membrane showed the best signal to noise (S/N) ratio. 
With the 90sec membrane, the flow rate was rapid, and this reduced the time frame for interaction 
between the target and test line antibodies thus reducing the observed signal. For 240sec 
membrane, due to the slower flow rate, there was longer exposure time for the test line immuno-
reaction which led to increased background. The 180sec membrane had an optimal flow rate that 
maximized the S/N ratio and was therefore chosen for further development of the LFB.  
The amount of antibodies on the test line was integral to the sensitivity of the developed 
MWCNT-LFB. The GaR IgG of then test line was dispensed different number of times and their 
S/N ratios compared. From Figure. 4.5. a, it is seen that S/N ratio gradually increased with 
cumulative number of dispense cycles. Five times (5x) dispensing gave the highest S/N ratio. From 
1 to 4 times dispensing, there was increase in the measured signal, however, the concentration of 
antibodies on the test line was not enough to give optimal test line intensities. Beyond 5x 
dispensing of the test line antibodies, there was increased background signal due to increased 
nonspecific interactions. For further development of the MWCNT-LFB, 5x dispense times of the 
test line was chosen. 
 62 
 
Figure 4.5. (a) Effect of membrane type on the S/N ratio of the assay (b) Effect of dispense cycles 
on of GaR IgG at the test line on the performance of the assay (c) Effect of running buffer 
composition on the S/N ratio of the assay. 
The immunoreactions in the sensor occurred in buffer solution. The composition of these 
buffers affected the extent of these interactions. From Figure 4.5. c, it is seen that the PBS 1%BSA 
had better performance than PBST 1%BSA and Tris-HCl 1% BSA buffers. Addition of PVP, a 
surfactant, further increased the S/N ratio in the PBS 1%BSA Buffer. Thence, PBS 1%BSA 
1%PVP was used as running buffer for subsequent testing. 
The quantity of antibodies immobilized on the MWCNT-antibody conjugates was also 
considered. A variation of the amount of GaR IgG used for conjugate preparation showed that 50 
µg of GaR IgG gave the best S/N ratio (Figure 4.6. a). At lower amounts of GaR IgG for conjugate 
preparation the lower S/N ratio observed was attributed to insufficient coverage of the MWCNT 
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which resulted in lower signals. The accessibility of the immobilized GaR IgG on the MWCNT 
was essential for the attainment of optimal sensitivity of the developed assay. Beyond 50 µg of 
GaR IgG there was a decrease in the S/N ratio. This decrease in S/N ratio was ascribed to 
overcrowding of conjugate IgG which introduced stearic hindrance. This reduced the efficiency of 
the immunoreactions at the test and control lines. Subsequent conjugates for the assay were 
prepared using 50 µg of GaR IgG. 
The intensities of test and control zones were greatly influenced by the amount of conjugate 
used for the assay. S/N ratio dependence on changing amount of conjugate per assay is shown in 
Figure 4.6. b. The highest S/N ratio was observed at 2 µL conjugate per assay. Under 2 µL 
conjugate, volume, the observed reduction in S/N ratio was attributed to inadequate amount of 
conjugate resulting in reduced test line intensities. Beyond 2 µL conjugate, there was reduced S/N 
ratio due to excess conjugate. The excess conjugate resulted in increased nonspecific interactions 
that led to high background signals. A volume of 2 µL conjugate was used for further testing of 
the developed CNT-LFSB. 
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Figure 4.6. (a) Effect of the amount of GaR IgG used for conjugate preparation on the S/N ratio 
of the assay. (b) Effect of the volume of conjugate per-assay-run used on the S/N ratio of the assay. 
In summary, the following experimental conditions gave the sensitivity while keeping 
background signals to a minimum: (a) using HF180MC100 to prepare the LFB; (b) dispensing test 
zone two times; (c) using PBS+1% BSA+1% PVP buffer as running buffer; (d) using 50 µg mL-1 
of GaR IgG to prepare the GaR IgG-MWCNT conjugates; (e) loading 2 µL of GaR IgG-MWCNT 
conjugates on conjugate pads.  
4.3.4. Analytical Performance 
Based on the optimized experimental conditions, sample solutions with different 
concentrations of rabbit IgG were tested on the CNT-based LFB. Each test was run three times. 
The captured MWCNTs on the test zone could be observed visually for qualitative data. 
Quantitative data was obtained by measuring the intensity of the test and control lines with a 
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portable strip reader. Figure 4.7 shows the typical photo images of the LFBs and corresponding 
responses from the strip reader. It is observed that the test line intensities increased with the rising 
concentrations of Rabbit IgG. The test line was quite visible even in the presence of 0.005 ng mL-
1 (5 pg mL-1) IgG, which could be estimated as a threshold for the qualitative detection of the target 
IgG. This threshold is 1000 times lower than previous report using GNP label.24 
 
Figure 4.7. Responses of MWCNT-based LFBs in the presence of different concentrations of 
rabbit IgG and corresponding photo images. 
In the blank test which had running buffer devoid of target rabbit IgG, there was no 
observable band on the test line. All tests showed a black control line which served as validation 
that the LFBs were working properly. From Figure 4.7, a series of well-defined peaks were 
observed, and the peak areas increased with increasing rabbit IgG concentration. The resulting 
calibration curve of the peak area(intensity) against the logarithm of Rabbit IgG concentration had 
two dynamic ranges of 5 pg - 100 pg mL-1 and 0.5 - 25 ng mL-1 (Figure 4.8.).  
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Figure 4.8. Calibration curves of the MWCNT-based LFB in the concentration range of (a) 5-
100pg mL-1 (b) 0.5 to 20 ng mL-1. 
The LOD (based on S/N ratio=3) was determined to be 1.32 pg mL-1, which is three orders 
lower than that of GNP-based LFB.18 Table 4.1. shows a comparison of the developed MWCNT-
LFB to some previously reported lateral flow assays. The MWCNT-LFB shows significant 
improvement in the LOD over the previous reports. To the best of our knowledge, this is the most 
sensitive protein detection on LFB which does not involve any form of signal amplification. The 
reproducibility of the MWCNT-based LFB was assessed by running six replicate tests in the 
absence and presence of 5 ng mL-1 rabbit IgG. The intensities of the test lines were all within a 
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standard deviation from the mean. Relative standard deviation of 3.8% and 4.3% respectively were 
calculated (data not shown). 
Table 4.1. Comparison of developed MWCNT-LFB to previous reports of protein detection on 
LFBs. 
Label Readout  
System 
Target Membrane  
material 
Detection 
 Limit 
Reference 
GNP Colorimetric Rabbit IgG Nitrocellulose 0.5 ng mL-1 18 
GNP/silica nanorods Colorimetric Rabbit IgG Nitrocellulose 0.01 ng mL-1 24 
CNT Electrochemical Human IgG Nitrocellulose 25 µg mL-1 153 
CNT Colorimetric Human Ferritin Cotton string 50 ng mL-1 154 
GNP-coated CNT Colorimetric Squamous cell 
carcinoma antigen 
Cotton string 2.32 ng mL-1 155 
CNT Colorimetric methamphetamine Nitrocellulose 62.5 ng mL-1 157 
CNT Colorimetric Rabbit IgG Nitrocellulose 1.32 pg mL-1 This work 
 
To confirm the specificity of the detection antibodies for the target rabbit IgG, 50 ng mL-1 
of three different proteins (mammaglobin, human IgG and CEA) and 50 U mL-1 of carbohydrate 
antigen 19-9(CA 19-9) were tested and compared to the signal from 5 ng mL-1 rabbit IgG. (Figure 
4.9.) There was no cross-reaction observed, indicating the GaR IgG was highly specific for the 
rabbit IgG target. 
 
Figure 4.9. Selectivity of MWCNT-based LFB. Concentration of rabbit IgG was 100 pg mL-1; CA 
19-9 was at 50 U mL-1; Mammaglobin, Human IgG and CEA were at 50 ng mL-1. 
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To assess the feasibility of applying the developed MWCNT-based LFB for protein 
detection under clinical settings, human plasma spiked with different concentrations of rabbit IgG 
was tested. The assay showed satisfactory performance in 10% human plasma with dynamic range 
of 1 ng mL-1 to 50 ng mL-1 as displayed in the calibration curve (Figure 4.10.). 
 
Figure 4.10. Calibration curve of MWCNT-based LFB for detection of rabbit IgG in spiked human 
plasma (10%). 
4.4. Conclusion 
A carbon nanotube-based lateral flow biosensor was successfully developed for 
quantitative detection of rabbit IgG. Under optimized conditions, 5 pg mL-1 of the target could be 
visually detected with the naked eye without any instrumentation. The LOD was 1.32 pg mL-1 
(S/N= 3), which is over 3 orders lower than previous report using gold nanoparticle as label.18 The 
MWCNT-based LFB showed high reproducibility and specificity which are essential for clinical 
applications. The biosensor was successfully able to detect rabbit IgG  spiked into human plasma 
within 20 mins. The developed MWCNT-LFBS holds enormous potential for the simple, fast and 
inexpensive point-of care  detection of various clinically important proteins. 
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5. MULTI-WALLED CARBON NANOTUBE-BASED LATERAL FLOW STRIP 
BIOSENSOR FOR THE QUANTITATIVE DETECTION OF CARCINOEMBRYONIC 
ANTIGEN (CEA) 
5.1. Introduction 
Pancreatic cancer, though it accounts for about 3% of cancer cases annually is the third 
leading cause of cancer related deaths in the United States after lung and breast cancers.158 Surgical 
resection of tumors is the primary treatment for pancreatic cancer, however at diagnosis most 
patients are beyond surgical intervention.98 There is the lack of reliable routine assay for the 
screening of pancreatic cancer to enable increased rate of early diagnosis.  
CEA was first discovered in fetal gut, liver, and pancreas. CEA levels are elevated in 
newborns, but the levels rapidly drop after birth. CEA is found elevated in various cancers of the 
gastrointestinal system as well as others like breast 159, lung 160 and ovarian 161 cancers. CEA levels 
in human serum can give information about recrudescence and metastatic state of a tumor.90 CEA 
is the most extensively used protein biomarker for cancer diagnosis and its levels are elevated in 
30-60% of pancreatic cancer patients.162 CEA has been detected mainly by ELISA. Though, 
ELISAs provides low to acceptable detection limits for CEA detection, they have the drawbacks 
of requiring long sample preparation and wash times, skilled labor for its operation and expensive 
plate readers. These drawbacks limit ELISA application for routine screening.  
Lateral flow Strip Biosensors are portable point-of-care devices that can rapidly detect 
cancer biomarkers with sensitivity and selectivity. Lateral flow assays have been used for the 
detection of various targets ranging from nucleic acids, proteins, carbohydrates and other smaller 
molecules. Various nanoparticles including gold nanoparticles (GNP) 15,18,119, fluorescent 
nanoparticles 23,120,121, GNP-coated silica nanorods 24,45 amongst others 26,28,116 have been used on 
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LFSBs. These nanoparticles have provided low to acceptable sensitivities; however, GNPs are the 
most widely used transducers for lateral flow biosensor applications. GNP lateral flow biosensors 
have gained patronage because of their red color that facilitates visual detection, and their ease of 
synthesis and conjugation to biorecognition elements. Also, GNP based LFSBs have limited 
sensitivity for detecting very low concentrations of biomarkers. 
In previous work (Chapter 4), protein biomarker detection was demonstrated using 
MWCNTs as transducers. The MWCNT-based biosensor enabled an over 400-fold reduction in 
detection limit for immunoglobulin detection as compared to the GNP-based LFSB system. CNTs 
have the advantage of having intense black color that gives sharp contrast and facilitates the visual 
detection of analyte. Further, CNTs have large aspect ratio that allows the immobilization of 
increased amounts of biorecognition elements. 
Here, a MWCNT-based LFSB is developed for the ultrasensitive detection of CEA. The 
assay depended on the capture of CEA between a pre-immobilized capture antibody and a 
MWNCT-antibody conjugate. The accumulation of MWCNTs on the test zone enabled the visual 
detection of CEA. Quantitative data was collected using a portable strip reader. 
5.2. Experimental Section 
5.2.1. Apparatus 
The Airjet AJQ 3000 dispenser, Biojet BJQ 3000 dispenser, Clamshell Laminator, and 
Guillotine Cutting Module CM 4000 were purchased from Biodot LTD (Irvine, CA, USA). 
Quantitative data was collected using a portable test strip reader (DT2032) purchased from 
Shanghai Goldbio Tech. Co., LTD (Shanghai, China).  
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5.2.2. Reagents and Materials 
Carboxylated multi-walled carbon nanotubes (carboxyl-MWCNT) (purity > 95 wt%) was 
purchased from Sun NanoTech (Nanchang, Jiangxi Province, China). Native CA 19-9 (30-AC14) 
and native CEA protein (30-1819) was purchased from Fitzgerald Industries International (Acton, 
MA, USA). CEA antibodies with catalogue numbers PIMIC0101 and PIMIC0102 were purchased 
from Fisher Scientific (Hampton, NH, USA). The CEA antibodies, PIMIC0101 and PIMIC0102, 
were designated CEA Ab B and CEA Ab A respectively. Human mammaglobin was purchased 
from Creative BioMart (Shirley, NY, USA). Goat anti-Mouse IgG (GaM IgG) and thrombin were 
obtained from Thermo Fisher Scientific, Inc. (Rockford, IL, USA). 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) , N-
hydroxysulfosuccinimide (sulfo-NHS), 2-(4-Morpholino) ethanesulfonic acid (MES), tween 20, 
triton X-100, bovine serum albumin (BSA), sucrose, polyvinylpyrrolidone (PVP), phosphate 
buffer saline (0.01 M PBS, pH 7.4) and trizma hydrochloride buffer solution (Tris-HCl, 1.0 M, pH 
8.0) were purchased from Sigma–Aldrich (St. Louis, MO, USA) and were used without further 
purification. Glass fibers (GFCP000800), cellulose fiber sample pads (CFSP001700), 
nitrocellulose membranes (HFC090MC100, HFC180MC100, HFC240MC100) were purchased 
from Millipore (Billerica, MA, USA). All the chemicals used in this study were analytical reagent 
grade. Solutions used were prepared with ultrapure (≥18M Ω) water from Millipore Milli-Q water 
purification system (Billerica, MA, USA). 
5.2.3. Preparation of MWCNT-Anti-CEA Antibody Conjugate 
Multi-wall carboxylated MWCNTs was suspended in acidic solution (HNO3:H2SO4, 1:3). 
The suspension was then kept under ultrasonication for 3hours. The acid treatment served to 
shorten and further add carboxyl groups onto the surface of the MWCNTs. The shortened CNTs 
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were then washed by centrifugation until the pH of the supernatant was neutral. To activate the 
carboxyl groups, the shortened MWCNTs were then resuspended in MES buffer pH=4.7 
containing EDC (9.6 mg) and sulfo-NHS (5.43 mg). The mixture was incubated for 30 mins with 
gentle shaking followed by centrifugation at 10,000 rpm for 15mins to wash the carbon tubes. The 
washing step was repeated two additional times. Activated carboxyl-MWCNT was resuspended 
in PBS and CEA Ab A (37.5µg) was added to a final volume of 1mL. the mixture was incubated 
overnight at 4°C with gentle shaking. The MWCNT-CEA Ab A conjugates were washed by 
centrifuging at 5000 rpm for 5mins. The washing step was repeated 3 times. The prepared 
MWCNT-CEA Ab A conjugates were finally resuspended in eluent buffer (20 mM 
Na3PO4·12H2O, 5% BSA, 10% sucrose, and 0.25% Tween-20) and stored at 4°C until used. 
5.2.4. Preparation of the MWCNT-Based LFSB for CEA Detection 
The developed MWCNT-based LFSB was composed of 3 major components (conjugate 
pad, nitrocellulose membrane and absorption pad) all assembled on a sticky plastic backing layer 
(Figure 5.1.). 
 
Figure 5.1. Setup of developed MWCNT-based LFSB for the detection of CEA. 
 73 
 The conjugate pad measured 21 x 300mm and was composed of porous glassy fiber that 
held MWCNT-CEA Ab A conjugates. The conjugate pad was spongy to ensure it held enough 
conjugate and was able to release conjugates upon wetting. The nitrocellulose membrane (25 ×300 
mm) supported the test and control zones of the developed biosensor. CEA Ab B and goat anti-
mouse IgG were dispensed on the nitrocellulose as the test and control lines respectively. After 
dispensing, the nitrocellulose membrane was dried at 37°C for 1 hour and stored at 4°C until used. 
The absorption pad was composed of cellulose fiber which absorbed assay fluids and drove the 
capillary movement of fluids during test runs. All three components were assembled on a non-
pervious plastic backing layer. The components overlapped by at least 2mm to ensure continuous 
fluid flow. The assembled biosensor was then cut into 3mm wide strips with the guillotine cutter 
and stored at 4◦C until used. 
5.2.5. Assay Procedure 
MWCNT-CEA Ab A conjugates (6uL) were dispensed onto the conjugate pad using a 
micropipette and allowed to air-dry for 5 mins. Sample CEA prepared in running buffer (PBS + 
10% BSA) with total volume of 100 µL was applied to the LFSB. The sample moved through the 
biosensor towards the absorption pad by capillary action. After 20 mins, 100 µL of running buffer 
was added to wash the strip. The wash helped remove any nonspecifically adsorbed conjugates on 
the LFSB which led to the removal of background signals. For qualitative data, the test and control 
line signals could be observed with the naked eye after 20 mins. Quantitative data was obtained 
by reading the test and control line band intensities with a portable strip reader. 
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5.3. Results and Discussion  
5.3.1. Principle of the Developed MWCNT-Based LFSB for CEA Detection 
The working principle of the developed biosensor is as depicted in Figure 5.2. CEA Ab B 
and goat anti-mouse IgG were pre-immobilized on the nitrocellulose membrane as test and control 
lines respectively. CEA Ab A, coated onto MWCNTs to form the MWCNT-CEA Ab A conjugates 
served as the detection antibody. In the presence of sample, the solution moved along the biosensor 
by capillary action. Upon reaching the pre-dried conjugates, the conjugates were rehydrated, and 
target CEA underwent an immunoreaction with the CEA Ab A of the conjugate to form a 
MWCNT-CEA Ab A-CEA complex. The complex continued moving along the membrane and 
was captured on the test line by a second immunoreaction between the CEA component of the 
complex and the test line’s pre-immobilized CEA Ab B (Figure 5.2. a). 
CEA dependent accumulation of MWCNT on the test line resulted in a black band which 
was observable with the naked eye. Excess conjugates were captured on the control line by an 
immunoreaction between the CEA Ab A of the MWCNT-CEA Ab A conjugate and the goat anti-
mouse IgG on the control line. This resulted in a second black band that served as verification that 
the assay was working properly (Figure 5.2. a). In the absence of target CEA, there was no 
observable black band on the test line (Figure 5.2. b). A single black band was observed on the 
control line. For qualitative data, the black bands on the strips were observed with the naked eye. 
To get quantitative data, the test and control line black band intensities were measured with 
a portable strip reader (Figure 5.2. c). The reader captured images with an inbuilt camera and 
converted the pixel intensities of the test and control lines into gaussian curves which were 
displayed on the screen of a computer. The peak areas on the computer display correlated with the 
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amount of MWCNTs that were immobilized on the test line, which in turn correlated with the 
concentration of CEA in the test sample. 
 
Figure 5.2. Principle of the MWCNT-based lateral flow strip biosensor for CEA detection (a) 
Capture of MWCNT on test and control lines in the presence of CEA (b) Capture of MWCNTs on 
the control line in the absence of CEA (c) Reading the test and control line intensities using a 
portable strip reader. 
5.3.2. Optimization of Experimental Parameters 
The performance of the assay depended on several factors like the membrane type used, 
dispense time of the test line, buffer composition, amount of antibodies for conjugate prep and the 
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volume of conjugates used). These assay conditions were optimized to obtain the best sensitivity 
and reproducibility with minimal nonspecific adsorption. 
The time window for the immunoreactions that occurred on the test and control lines were 
dependent on the flow rate of the nitrocellulose membrane used. If the flow rate was very slow the 
time window for the immunoreactions was increased and there could be increased non-specific 
interactions. Conversely, if the flow rate was too rapid there could have been insufficient time for 
the target CEA to be efficiently captured on the test zone. Three membranes HF090MC100, 
HF180MC100 and HF240MC100 with flow rates 90, 180 and 240 seconds per 4cm respectively 
as reported by the manufacturer were tested for their performance on the LFSB (Figure 5.3. a). 
The 90 second membrane showed the highest S/N ratio. At slower flow rates (180 and 240 secs) 
the S/N ratio of the assay reduced. This reduction in S/N ratio was because of increased 
background signals due to non-specific adsorption. The 90 sec membrane was thus chosen for 
further development of the LFSB. 
The dispense times of the test line also played a critical role in the performance of the 
assay. CEA Ab B at concentration of 1 mg mL-1 was dispensed 1, 2, 3 and 4 times on the 
nitrocellulose membrane and their performance compared (Figure 5.3. b). A 1-time dispense of 
the test line gave the best S/N ratio. The antibody concentration was optimal to allow efficient 
capture of target CEA on the test line. At higher dispense times (2, 3 and 4 times), there was 
increased background that led to a rapid reduction in the S/N ratios of the assay. For further 
development of the assay, 1-time dispense of the test line was chosen. 
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Figure 5.3. (a) Effect of different types of nitrocellulose membranes on the S/N ratio of the assay 
(b) Effect of the dispensing times of Anti-CEA Ab B on the S/N ratio of the assay. (c): Effect of 
buffer type on the S/N ratio of the assay (d) Effect of BSA percentage in buffer on the S/N ratio 
of the assay. 
The next line of optimization was variation of buffer conditions to determine the best buffer 
for the developed assay. Three buffers (PBS + 1% BSA, PBST+ 1% BSA, Tris-HCl + 1% BSA) 
were tested for their performance on the lateral flow biosensor (Figure 5.3. c). PBS + 1% BSA 
showed the highest S/N ratio, however, some non-specific background signals were observed. The 
amount of BSA in the running buffer was further optimized to decrease non-specific interactions 
and thus increase the S/N ratio of the assay. BSA at varying concentrations (1, 2, 4, 6, 8, 10, 12 % 
w/v in PBS) were tested for their performance on the developed biosensor (Figure 5.3. d). The 
BSA successfully decreased the background signals and increased the S/N ratio up to a 
concentration 10% BSA. Beyond 10% the signal intensity of the test line was reduced. PBS + 10% 
BSA was thus chosen as running buffer for further development of the biosensor.  
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Figure 5.4. (a) Effect of the amount of anti-CEA Ab A used for conjugate preparation on the S/N 
ratio of the assay. (b) Effect of the volume of conjugate used on the S/N ratio of the assay. 
The amount CEA Ab A used for the conjugate preparation was the next parameter to be 
optimized. Here, varying amounts of CEA Ab A (10, 20 37.5, 50 and 70 µg) were used for the 
preparation of conjugates and their performance compared on the LFSB (Figure 5.4. a). At low 
concentrations (10 and 20ug) of CEA Ab A, the S/N ratios was low, and this was attributed to the 
conjugate not having enough antibodies to enable efficient capturing of target CEA onto the test 
line. Conversely, at higher concentrations the observed decline in the S/N ratio of the assay was 
resultant of overcrowding of the antibodies on the MWCNT surface which led to stearic hindrance 
and thus reduced efficiency of the immunoreactions during the test run. The best performance was 
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observed when 37.5 µg of anti CEA Ab A was used for the conjugate preparation. For further 
development of the assay 37.5µg of CEA Ab A was used for conjugate preparation. 
Finally, the conjugate volume used per assay run also significantly affected the 
performance of the assay. The assay was performed using varied volumes (1, 2, 3, 4 ,5 ,6 µL) of 
conjugates and their S/N ratios compared (Figure 5.4. b). At low conjugate volume (1µL), there 
was lowered S/N ratio which was attributed to insufficient conjugates presence to facilitate the 
efficient capture of target CEA. The highest S/N ratio was observed at 2 µL conjugate volume. At 
higher volumes beyond 2µL, the observed reduction in S/N ratios was attributed to increased non-
specific interactions that led to elevated background signals. A conjugate volume of 2 µL was used 
for further development of the MWCNT-based LFSB. 
5.3.3. Analytical Performance 
Under optimized assay conditions (90-second nitrocellulose membrane, 1-time dispense of 
test line, PBS + 10% BSA running buffer, 37.5µg CEA Ab A for conjugate preparation and 2µL 
conjugate volume), the developed MWCNT-based LFSB was tested in the presence of varying 
amounts of CEA standards prepared in running buffer. All tests were run in triplicates.  
Typical images of the assay in the presence of increasing CEA concentrations (0.1 to 25ng 
mL-1) were as displayed in Figure 5.5. a. The test line intensities increased with increasing 
concentration of target CEA. The test strips showed no test line bands in the absence of target CEA 
which indicated that there was negligible non-specific adsorption. The visual LOD using the naked 
eye was 0.1ng mL-1 of CEA which was 50 times lower than previous report of 5ng mL using GNPs 
as labels.90 The test line intensities were read with a portable strip reader for quantitative data. The 
measured test line intensities were plotted against the CEA concentration to obtain a calibration 
curve (Figure 5.5. b). The assay showed good linearity (R2= 0.9955), with dynamic range of 0.1 
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ng mL-1 to 25 ng mL-1. The equation of the calibration curve was y = 67.33x + 48.739; where y 
and x were the test line intensities and the CEA concentrations respectively. The assay showed 
good reproducibility. Six replicate tests were each performed at CEA concentrations 0, 1 and 15 
ng mL-1 and the relative standard deviations were 4.2%, 3.1% and 5.3% respectively (data not 
shown). 
 
Figure 5.5. (a) Photo images of CNT-based LFSB in the presence of varying concentrations of 
CEA (b) Calibration curve of CEA detected on developed MWCNT-based lateral flow strip 
biosensor. Each data point represents the average value obtained from three different 
measurements. 
The selectivity of the developed assay was assessed by testing the assay in the presence of 
some probable interfering proteins (C4B-alpha, Human IgG, Mammaglobin, and Thrombin at 
concentrations of 100ng/mL-1; CA 19-9 at concentration of 100 U mL-1) that may be present in 
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human plasma samples (Figure 5.6.). As shown in the graph, the signal for the CEA at 
concentration of 5ng mL-1 was very high compared to the signal for the other molecules (which 
were similar to the signal of the blank). This confirmed the excellent selectivity of the developed 
MWCNT-based LFSB for the detection of CEA. 
 
Figure 5.6. Selectivity of the developed MWCNT-based LFSB (concentration of CEA was 5ng 
mL-1, CA 19-9 was 100 U mL−1, C4B-aplha, Human IgG, Mammaglobin, Thrombin were 100 ng 
mL−1). 
5.4. Conclusion 
A MWCNT-based LFSB was successfully developed for the quantitative detection of 
CEA. Under optimized assay conditions the developed biosensor had a detection limit of 0.1ng 
mL-1 CEA which was about 20-fold improvement in detection limit over the GNP-based LFSB for 
CEA (Chapter 3). The developed assay showed a good linear dynamic range of 0.1 ng mL-1 to 25 
ng mL-1. Further work will aim to apply the developed assay for the screening of CEA in clinical 
samples. The assay shows great promise for application for CEA detection in medical diagnostics 
and screening, particularly in low resourced settings. 
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6. MULTI-WALLED CARBON NANOTUBE-BASED LATERAL FLOW STRIP 
BIOSENSOR FOR THE QUANTITATIVE DETECTION OF CARBOHYDRATE 
ANTIGEN (CA 19-9) 
6.1. Introduction 
Over the past few years pancreatic cancer has risen to be the third leading cause of cancer 
related deaths even though it is the thirteenth leading cause of cancer in the United States.158 Over 
the years there has been little improvement in the survival rates of pancreatic cancer patients. 
Pancreatectomy remains the most effective way of treating pancreatic cancer. However, only about 
5-25% of pancreatic cancer patients are prospects for curative pancreatectomy at diagnosis.163 
Pancreatic cancer has been diagnosed with imaging techniques such as computer tomography, 
angiography, magnetic resonance imaging, endoscopic ultrasound etc. as reviewed.164 Tissue 
biopsies may also be examined by histochemical methods. These methods are expensive, require 
hospital visitation and have the need for skilled technical expertise. As such, they are not suitable 
for routine disease screening and monitoring purposes. 
The screening of biomarkers present in blood presents an alternate avenue for the screening 
and monitoring of pancreatic cancer. Various biomarkers have been reported for the screening of 
pancreatic cancer.98,165 However, carbohydrate antigen (CA 19-9) remains the only USFDA 
approved biomarker for pancreatic cancer. CA 19-9 was first isolated from colorectal carcinoma 
and later pancreatic carcinoma.74 Since then CA 19-9 has been reported in other cancers of the 
gastrointestinal system 166 and other cancers like those of the breast 167 and lungs 168. Still, CA 19-
9 remains the best single biomarker for the management of pancreatic cancer. Accordingly, 
developing sensitive biosensors for the detection of CA 19-9 could help better manage and monitor 
pancreatic cancer cases.  
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CA 19-9 has been detected by various methods such as radioimmunoassay, ELISAs, 
western blotting and some electrophoretic methods.169,170 Clinically, ELISAs are the gold standard 
for CA 19-9 detection and many commercial ELISA assays are available for CA19-9 detection.169 
Though ELISAs provide acceptable sensitivity, they have the disadvantages of having long assay 
times, multiple washing steps, and the requirement for skilled labor and expensive plate readers.  
Lateral flow strip biosensors provide a simple, rapid and inexpensive alternative detection 
technique. In Chapter 2, a lateral flow assay was developed using GNPs as transducers for the 
detection of CA 19-9. Though this assay showed acceptable sensitivity, there is the need to develop 
more sensitive assays to enable more efficient monitoring of CA 19-9 levels. Based on the signal 
enhancement observed in the MWCNT-LFSB developed for the detection of proteins in human 
plasma (Chapter 4), a MWCNT-based LFSB for the detection of CA 19-9 is discussed in this 
chapter. Anti-CA 19-9 was covalently linked to the surface of MWCNT and used to detect CA 19-
9 in a sandwich type immunoassay. The large surface area and the intense black color of the 
MWCNTs led to improved sensitivity over the GNP-based LFSB for the detection of CA 19-9. 
6.2. Experimental Section 
6.2.1. Apparatus 
The Airjet AJQ 3000 dispenser, Biojet BJQ 3000 dispenser, Clamshell Laminator, and 
Guillotine Cutting module CM 4000 were purchased from Biodot LTD (Irvine, CA, USA). 
Quantitative data was collected using a portable test strip reader (DT2032) purchased from 
Shanghai Goldbio Tech. Co., LTD (Shanghai, China).  
6.2.2. Reagents and Materials  
Carboxylated multi-walled carbon nanotubes (carboxyl-MWCNT) (purity > 95 wt%) was 
purchased from Sun NanoTech (Nanchang, Jiangxi Province, China). Native CA 19-9 (30-AC14), 
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native CEA protein (30-1819), and mouse anti-CA 19-9 antibodies with catalogue numbers of 10-
CA19A and 10-CA19 B was purchased from Fitzgerald Industries International (Acton, MA, 
USA). The anti-CA 19-9 antibodies were designated anti-CA 19-9 AbA and anti-CA 19-9 AbB 
respectively. Human mammaglobin was purchased from Creative BioMart (Shirley, NY, USA). 
Goat anti-Mouse IgG (GaM IgG) and thrombin were obtained from Thermo Fisher Scientific, Inc. 
(Rockford, IL, USA). 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), N- hydroxyl-
sulfo succinimide (sulfo-NHS), 2-(4-Morpholino) ethanesulfonic acid (MES), tween 20, triton X-
100, bovine serum albumin (BSA), sucrose, polyvinylpyrrolidone (PVP), hexadecyltrimethy-
lammonium bromide (CTAB) phosphate buffer saline (0.01 M PBS, pH 7.4) and trizma hydro-
chloride buffer solution (Tris-HCl, 1.0 M, pH 8.0) were purchased from Sigma–Aldrich (St. Louis, 
MO, USA) and were used without further purification. Glass fibers (GFCP000800), cellulose fiber 
sample pads (CFSP001700), nitrocellulose membranes (HFC090MC100, HFC180MC100, 
HFC240MC100) were purchased from Millipore (Billerica, MA). All the chemicals used in this 
study were analytical reagent grade. Solutions used were prepared with ultrapure (≥18M Ω) water 
from Millipore Milli-Q water purification system (Billerica, MA, USA). 
6.2.3. Preparation of MWCNT-Anti-CA 19-9 AbA Conjugate 
MWCNTS with activated carboxyl groups were prepared as previously described (Section 
5.2.3). The prepared MWCNTs suspended in PBS at a concentration of 0.5 mg MWCNT per 
milliliter of buffer. CA 19-9 AbA (80 µg) was then added, and the mixture was incubated overnight 
with gentle shaking at 4°C. The prepared MWCNT-anti-CA 19-9 AbA was washed with PBS by 
centrifugation at 5000 rpm for 5 mins. The washing step was repeated 3 times. The supernatant 
was monitored by UV absorbance (280 nm) measurements to ensure no protein absorption was 
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present in the supernatant. The prepared MWCNT-anti CA 19-9 Ab A conjugates were 
resuspended in Eluent buffer (20 mM Na3PO4·12H2O, 5% BSA, 10% sucrose, and 0.25% Tween-
20) and stored at 4°C until used. 
6.2.4. Preparation of the MWCNT-Based LFSB for CA 19-9 Detection 
The setup for the developed MWCNT-based LFSB for the detection of CA 19-9 was as 
shown in Figure 6.1. The biosensor was composed of three major components (conjugate pad, 
nitrocellulose membrane and absorption pad). The three components were assembled on a sticky 
plastic backing layer.  
The conjugate pad was a glassy fiber that measured 21 x 300mm. The glassy fiber was 
porous to ensure the pad could hold a large volume of conjugate. The pad was also able to release 
the dried conjugates upon wetting. The nitrocellulose membrane supported the test line and control 
line antibodies. Anti-CA 19-9 AbB and goat anti-mouse IgG were dispensed as the test and control 
lines respectively. The absorption pad was the final component, and this absorbed excess reagents 
and created capillary force to drive fluid movement during the assay run. The components were 
assembled onto the sticky backing layer and were allowed to overlap by at least 2mm to ensure 
continuous movement of the solvent. The assemblies were then cut into 3mm width strips and 
stored at 4°C until used. 
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Figure 6.1 Scheme of developed MWCNT-based LFSB for the detection of CA 19-9. 
6.2.5. Assay Procedure 
MWCNT-anti-CA 19-9 AbA conjugates were pipetted onto the conjugate pad and allowed 
to dry for 5mins. Native CA 19-9 prepared in running buffer (PBS + 1%BSA + 1.5mM CTAB) 
with volume 100µLwas applied to the LFSB. The solution moved across the test strip by capillary 
action. After 20 mins, the strip was washed with 100 µL of running buffer. The washing step 
served to remove any nonspecifically adsorbed conjugates which reduce background signals. The 
test line could be visually examined with the naked eye for qualitative data. For quantitative data, 
the test and control line intensities were measured with a portable strip reader. 
6.3. Results and Discussion  
6.3.1. Principle of the Developed MWCNT-Based LFSB for CA 19-9 Detection 
The developed assay relied on the CA 19-9 dependent accumulation of MWCNT on the 
test line to enable visual detection of CA 19-9 (Figure 6.2. a). The nitrocellulose membrane of the 
LFSB supported pre-immobilized anti-CA 19-9 AbB and goat anti-mouse IgG that served as the 
test and control lines respectively. Anti-CA 19-9 AbA component of the MWCNT- anti-CA 19-9 
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AbA conjugate served as the detection antibody. In the presence of sample containing target CA 
19-9, there was an immunoreaction between the CA 19-9 and the anti-CA 19-9 AbA component 
of the MWCNT-anti-CA 19-9 AbA conjugate to form a MWCNT-anti-CA 19-9 AbA-CA 19-9 
complex. The complex moved along the strip and upon encountering the test line, were captured 
by an immunoreaction between the CA 19-9 component of the complex and the test line anti-CA 
19-9 AbB (Figure 6.2. a). The CA 19-9 dependent accumulation of MWCNT on the test line 
resulted in a black colored band that was visible to the naked eye. Excess conjugates moved further 
along the test strip and were captured by the control line goat anti-mouse IgG which resulted in a 
second black band (Figure 6.2. a). In the absence of target CA 19-9, there was no accumulation 
of MWCNTS on the test line, however, there was capture of the MWCNT-anti-CA 19-9 AbA 
conjugate at the control line which verified the assay was working well (Figure 6.2. b). To get 
quantitative data, the test and control line intensities of the test strips were read with a portable 
reader connected to a laptop. The strip reader captured images of the test and control lines and 
used their pixel intensities to construct gaussian curves which was read on the laptop screen 
(Figure 6.2. c). The area under the curve gave information about the amount MWCNTs that were 
immobilized on the test line, which in turn correlated with the concentration of CA 19-9 in the test 
sample. 
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Figure 6.2. Working principle of the MWCNT-based lateral flow strip biosensor for CA 19-9 
detection (a) Capture of MWCNT on test and control lines in the presence of CA 19-9 (b) Capture 
of MWCNTs on the control line in the absence of CA 19-9 (c) Reading the test and control line 
intensities using a portable strip reader. 
6.3.2. Optimization of Experimental Parameters 
The performance of the assay depended on parameters like the nitrocellulose membrane 
type used, dispense times of the test line, the composition of the running buffer, amount of 
antibodies used for conjugate preparation and the volume of conjugates used per test. These 
parameters had to be optimized to ensure the highest sensitivity while keeping background signal 
at a minimum.  
The flow rate of the membrane that supported the test and control lines dictated the time 
window within which the immunoreactions at the test line would occur. Three membranes 
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(HFC090MC100, HFC180MC100, HFC240MC100) with flow rates of 90 secs, 3 mins and 4 mins 
per 4cm of membrane respectively were tested for their performance on the developed LFSB 
(Figure 6.3. a). From the chart, it is observed that the 90-sec membrane gave the best S/N ratio. 
There was a marked reduction in performance when the 3-min and 4-min membranes were used. 
The reduction in S/N ratios was because of increased background signals. The 90- sec membrane 
was therefore chosen for further development of the assay. 
The anti-CEA AbB dispense times for the test line preparation was also optimized. Anti-
CA 19-9 AbB at concentration of 1 mg mL-1 was dispensed varying times (1, 2, 3, 4 ,5x) and their 
S/N ration compared (Figure 6.3. b). At lower dispense times (1,2 and 3x) lowered S/N ratios 
were observed which was attributed to inadequate antibody concentration on the test lines. There 
were therefore lowered test line intensities that led to the observed reduction in S/N ratios. The 
highest S/N ratio was observed at 4x dispense cycles of the test line. Beyond 4x dispense there 
was a reduction in the S/N ratio as a result of increased background signals resulting from increased 
nonspecific adsorption. For further development of the assay, the test line anti-CA 19-9 AbB was 
dispensed 4 times. 
The buffer composition also affected the assay performance. Target CA 19-9 was prepared 
in different buffers (PBS + 1% BSA, PBS + 1% BSA + 1.5Mm CTAB, PBST + 1% BSA, PBST 
+ 1% BSA + 1.5Mm CTAB, Tris-HCl +1% BSA, Tris-HCl +1% BSA + 1.5mM CTAB) and their 
S/N ratios compared (Figure 6.3. c). Tris-HCl +1% BSA + 1.5mM CTAB showed the best 
performance and was thus chosen for further development of the assay. 
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Figure 6.3. (a) Effect of different types of nitrocellulose membranes on the S/N ratio of the assay. 
(b) Effect of the dispensing times of Anti-CA 19-9 AbB on the S/N ratio of the assay. (c) Effect 
of buffer type on the S/N ratio of the assay. 
The amount of anti-CA 19-9 AbA used for the preparation of the conjugate was the next 
line of optimizations performed. Varying amounts (20, 40, 60, 80, 100, 120, 160 µg) of anti-CA 
19-9 AbA was used for the preparation of MWCNT-anti-CA 19-9 AbA and the S/N ratios 
compared (Figure 6.4. a). The S/N ratio peaked at 80 µg. Beyond 80 µg of antibody the S/N ratios 
dropped as the test line intensities reduced. At the higher concentrations, there was overcrowding 
of the antibodies on the MWCNT surface which resulted in stearic hindrance and thus reduced 
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efficiency of the immunoreactions during the test run. 80 µg of anti-CA 19-9 was therefore chosen 
for further development of the assay. 
 
Figure 6.4. (a) Effect of the amount of anti-CA 19-9 AbA used for conjugate preparation on the 
S/N ratio of the assay (b) Effect of the volume of conjugate used on the S/N ratio of the assay. 
The amount of conjugate dispensed onto the conjugate pad per assay ran also had a huge 
influence on the performance of the assay. Varying volumes of conjugates were tested on the 
developed LFSB and their S/N ratios compared (Figure 6.4. b). The highest S/N ratio was 
observed when 4 µL of conjugate was used. Lower volumes of conjugate gave inadequate 
sensitivity, and higher volumes showed increased background signals. 4 µL of MWCNT-anti CA 
19-9 AbA conjugate was thus chosen for further testing. 
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6.3.3. Analytical Performance 
Under optimized conditions (90-sec membrane, 4x dispense cycles of the test line, Tris-
HCl + 1%BSA + 1.5mM CTAB running buffer, 80µg anti-CA 19-9 AbA for conjugate 
preparation, 4 µL of conjugate per assay run) the developed MWCNT-based LFSB was used to 
detect varying concentrations of CA 19-9 prepared in running buffer. Typical photo images of the 
biosensor’s response to the varying CA 19-9 concentrations were are as shown in Figure 6.5. a. 
As expected, the intensity of the test line black bands increased with increasing concentration of 
target CA 19-9. In the absence of target, there was no observable black band on the test line which 
indicated that the optimization process successfully eliminated non-specific adsorption of the 
conjugate onto the test zone. The visual detection limit was 1 U mL-1 which was a five-fold 
reduction compared to the GNP-based LFSB for CA 19-9 detection. 
 
Figure 6.5. (a) Photo images of MWCNT-based LFSB in the presence of varying concentrations 
of CA 19-9 (b) Calibration curve of CA 19-9 detected on developed MWCNT-based lateral flow 
strip biosensor. Each data point represents the average value obtained from three different 
measurements. 
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For qualitative data (yes/no) the strips were observed with the naked eye. To get 
quantitative data, the test line intensities were read with a portable strip reader. The intensities of 
the test lines were plotted against the concentrations of CA 19-9 to obtain a calibration curve as 
displayed in Figure 6.5. b. The calibration curve showed good linearity (R2= 0.9906) with a linear 
dynamic range from 1 U mL-1 to 50 U mL-1. The equation of the curve was y = 30.134x + 55.567; 
where y and x were the test line intensities and the CA 19-9 concentrations respectively. The 
detection limit was calculated to be 0.14 U mL-1 (S/N ratio =3) which was an improvement over 
the GNP-based LFSB for CA 19-9 (5U mL-1). The assay showed good reproducibility. Six parallel 
tests were each performed at CA 19-9 concentrations of 1 and 35 U mL-1 and the relative standard 
deviations were 7.2% and 5.1% respectively (data not shown). 
 
Figure 6.6. Selectivity of the developed MWCNT-based LFSB (concentration of CA 19-9 was 10 
U mL-1; CEA, Mammaglobin, Human IgG, C4B-aplha and Thrombin were at 100 ng mL−1). 
The assay also showed excellent selectivity as shown in Figure 6.6. The signal for CA 19-
9 at concentration of 10 U mL-1 was much higher than the signal intensity for the other proteins 
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that were present at over 10-fold higher concentrations. The signal for the other proteins were like 
the signal for the blank. 
6.4. Conclusion 
A quantitative MWCNT-based LFSB was successfully developed for the detection of CA 
19-9. The assay successfully detected varying concentrations of CA 19-9 in buffered solution and 
had an improved detection limit of 0.14 U mL-1 (S/N ratio = 3) which was about 35-fold more 
sensitive than the GNP-based LFSB for CA 19-9.  The assay was capable of detecting CA 19-9 in 
under 30minutes and shows great potential for application as a point-of-care screening tool. 
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7. GOLD NANOPARTICLE-BASED LATERAL FLOW STRIP APTASENSOR FOR THE 
DETECTION OF EXOSOMES FROM HUMAN PLASMA 
7.1. Introduction  
Exosomes are small membrane bound biomolecular vesicles that are released from both 
healthy and cancerous cells. Various cargo like DNA, miRNA, lipids and proteins can be carried 
inside the exosome vesicles. The composition of the exosomal cargo and surface proteins is a 
reflection of the physiological and functional condition of the parent cell.171 Exosomes influence 
diverse pathological and physiological functions of the parent cells of origin and destination 
cells.172 In cancer, one of the fundamental determinants of cancer cell growth promotion and 
suppression is the tumor microenvironment. The tumor microenvironment is composed of 
fibroblasts, immune cells and extracellular matrix containing vesicles such as exosomes.173 
Exosomes in the tumor microenvironment help in localized cancer cell communication as well as 
communication with distant cells and tissues. Cancer cells are able to sort out oncoproteins and 
cancer related nucleic acids into exosomes which are then incorporated in adjacent healthy cells 
to drive neoplastic transition.174 Exosomes have also been reported to play a pivotal role in 
angiogenesis, transformation of extracellular matrix, immune evasion and resistance to 
chemotherapeutic drugs. 175–178  
In cancer patients, tumors and cancer cells may have up-regulated extracellular vesicle 
shedding, and higher levels of exosomes has been measured patient serum, however, more studies 
are required in this area. Exosomes are found in various bodily fluids such as blood and urine. 
Exosomes are therefore good candidates for diagnosis and prognosis of diseases, and for the 
monitoring of patient response to therapy. The use of exosomes for diagnostics is an emerging 
field of study that has gained traction. Ultracentrifugation has been predominantly used to separate 
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and purify exosomes from bodily fluids.179 More recent methods including nanomembrane 
concentrators, size exclusion chromatography (SEC), exosome precipitation, immunoaffinity 
capture and microfluidic based isolation techniques have been reviewed.180 
For diagnostic purposes, it is important to quantify exosomes upon isolation and 
purification. Enzyme linked immunosorbent assays (ELISA) has been used for the quantitation of 
exosomes. 181,182 ELISAs for exosome detection generally have the exosomes directly immobilized 
at the bottom of well plates. Upon blocking with agents such as bovine serum albumin (BSA), 
primary antibodies are introduced to bind to pre-immobilized exosomes. Enzyme labelled 
secondary antibodies are then added and in the presence of substrate a colored complex whose 
intensity reflects the number of exosomes is observed. Oliviera-Radríguez and coworkers 
developed an in-house ELISA suing antibodies for CD9, CD81 and CD63 cell surface proteins to 
detect exosomes from cell culture media.72 There are also commercially available kits such as 
ExoELISA™ and ExoQuant™ ELISA kits by Systems Biosciences and BioVision Inc. 
respectively which are used to quantify exosomes. Though the ELISA-based methods provide 
acceptable sensitivity, they suffer draw backs such as, multiple washing cycles leading to long 
assay times, requirement for refrigeration, and the need for skilled labor. Flow cytometric methods 
have also been used for exosome analysis.183 They have the advantage of being high throughput, 
and may provide information about individual exosomes. However, flow cytometric analysis of 
extracellular vesicles suffer setbacks such as data variation between different platforms, variation 
in analysis of data from laboratory to laboratory, and high background noise from light scattering 
as reviewed.184 Other methods of exosome analysis including electrochemical methods and 
fluorescent nanoparticle tracking analysis (NTA) have also been reviewed.185 NTA analysis allows 
for the characterization of individual exosome sizes and can also give information about bulk 
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exosome concentrations. These detection techniques offer unique advantages, however, high cost, 
poor miniaturization for in-field usage, and the need for skilled technical labor limit their 
application for routine screening.  
Lateral flow strip biosensors (LFSB) offer a rapid, low cost but sensitive and selective 
method of analysis. LFSBs traditionally rely on sandwich type immunoassay setup where a target 
is captured between an antibody immobilized on a solid support and a detection antibody linked 
to a nanoparticle transducer. Target dependent accumulation of the nanoparticles is measured to 
get quantitative data. Various nanoparticles including gold nanoparticles (GNP)15,18,72,119, carbon 
nanotubes25, fluorescent nanoparticles23,120,121, GNP-coated silica nanorods24,45 amongst 
others26,28,116 have been applied on lateral flow for the detection of a variety of targets. The intense 
red color of GNPs resultant of their surface plasmon properties makes GNPs the gold standard in 
LFSB transducers. GNP based LFSI have been used for the detection of proteins, cells and some 
small molecules.  
The class of LFSBs that rely on antibodies as biorecognition elements are termed lateral 
flow strip immunosensors (LFSI). Immunosensors have shortfalls such as high cost of production, 
batch to batch variation and long-term instability. As a result, LFSIs can suffer some 
inconsistencies in results and cause a divide between the current performance of LFSB and their 
expected low price and reliability.186 
Aptamers are a class of nucleic acids that can replace antibodies as biorecognition 
elements. Aptamers fold into unique primary, secondary and tertiary structures that enhance their 
binding and specificity. Aptamers are developed by a process termed Systematic Evolution of 
Ligands by Exponential Enrichment (SELEX). Aptamers have the advantages of being cheap and 
simple to chemically synthesize or modify. They are also redox insensitive and heat stable, and 
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therefore require no form of refrigeration. Aptamers have been developed for targets such as 
proteins, cells, heavy metals and some other small molecules.187 Aptamer based lateral flow assays 
are termed lateral flow strip aptasensors (LFSA). LFSAs have been developed for proteins and 
some small molecules.14,17,188 Also, Mao and coworkers successfully demonstrated the detection 
of ramos cells using a GNP-based lateral aptasensor.15 
Exosome detection has seen little attention on lateral flow strip biosensors. Oliveira-
Rodríguez and coworkers developed a LFSI utilizing anti-CD-9 and anti-CD81 antibodies for the 
detection of exosomes from culture media and bodily fluids.72 The assay though applied 
successfully, suffered a high LOD which limits its application. There remains the need for the 
development of more sensitive and selective point-of-care assays for exosome. 
Considering the unique advantages afforded by replacing antibodies with aptamers, a GNP- 
based LFSA that utilizes an aptamer previously developed189 for cell surface protein (EpCAM) is 
proposed for the detection of exosomes. EpCAM, a cell surface membrane protein that has been 
reported to be associated with various cancers including pancreatic cancer was chosen as a model 
target. Exosomes surface membranes can carry similar proteins as those expressed on the 
originating cells. In this work, exosomes were captured in a sandwich assay between the 
immobilized EpCAM aptamers on a solid support and aptamer labelled GNP. Under optimized 
conditions, the exosome dependent accumulation of GNP on the test zone resulted in a low 
detection limit of 1.3 x 103 exosomes/µL which was a significant improvement over previous 
report.72 The GNP-based LFSA shows promise for the low cost and rapid detection of exosomes 
isolated from clinical samples. 
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7.2. Experimental Section 
7.2.1. Apparatus 
The Biojet BJQ 3000 dispenser, Clamshell Laminator and Guillotine cutting module CM 
4000 used for the assembling of the LFSB were bought from Biodot LTD (Irvine, CA, USA). 
Strips were quantitatively read with a portable strip reader (DT2032) acquired from Shanghai 
Goldbio Tech. Co., LTD (Shanghai, China). Exosomes were isolated from human plasma by 
ultracentrifugation using Optima XE-90 ultracentrifuge purchased from Beckman Coulter, Inc 
(Indianapolis, IN, USA). Exosome were also isolated using qEVoriginal size exclusion columns 
purchased from Izon Science LTD (Medford, MA, United States). Strip images were captured with 
an S7 smart phone by Samsung Electronics (Seoul, South Korea). 
7.2.2. Reagents and Materials 
Gold (III) chloride (HAuCl2), phosphate buffered saline (0.01 M PBS, pH 7.4), Dulbecco's 
phosphate-buffered saline (DPBS), trizma hydrochloride buffer solution (Tris-HCl, 1.0 M, pH 
8.0), tween 20, triton X-100, bovine serum albumin (BSA), sucrose, sodium chloride (NaCl), 
magnesium chloride (MgCl2) and sodium phosphate tribasic deodecahydrate (Na3PO4.12H2O) 
were purchased from Sigma–Aldrich (St. Louis, MO, USA) and were used without further 
purification. Glass fibers (GFCP000800), cellulose fiber (CFSP001700), and nitrocellulose 
membranes (HFC090MC100, HFC135MC100, HFC180MC100) were purchased from Sigma–
Aldrich (St. Louis, MO, USA) for the fabrication of the LFSB platform. Streptavidin was 
purchased from Prospec-Tany Technogene Ltd (Ness-Ziona, Israel). Deoxyadenosine triphosphate 
(dATP) and goat anti-mouse IgG were purchased from Thermofisher Scientific (Waltham, MA, 
United States). Anti-EpCAM antibodies with catalogue numbers ABIN1684521 and 
ABIN4949645 were purchased from Antibodies-online Inc. (Atlanta, GA, United States). All 
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DNA sequences were purchased from Integrated DNA Technologies, Inc. (Coralville, CA, United 
States). The DNA sequences used in the assay are as follows: 
Biotinylated EpCAM capture probe: 5’-/Biosg/-CACTACAGAGGTTGCGTCTGTCCCACGT 
TGTCATGGGGGGTTGGCCTG-3’ 
Thiolated EpCAM detection Probe: 5’-ThioMC6-D/CACTACAGAGGTTGCGTCTGTCCCAC 
GTTGTCATGGGGGGTTGGCCTG-3’ 
Biotinylated control line Probe: 5'-/Biosg/ATATATATATATATATA-3' 
Thiolated control probe: 5'-ThioMC6-D/TATATATATATATATAT-3' 
All reagents were analytical grade. All solutions used in the study were prepared in 
ultrapure (≥18M Ω) water from Millipore Milli-Q water purification system (Billerica, MA, USA). 
7.2.3. Preparation of GNPs 
GNPs with diameters 13nm ± 3.5 were prepared as previously described.119,190 All glass-
ware used for the preparation of the GNPs were washed with detergent and further cleaned by 
soaking in aqua regia (3:1; HCl:HNO3). The glassware was then washed with copious amounts of 
distilled water and dried out. HAuCl4 stock solution (50% w/v) was prepared in ultrapure water. 
Fifty microliters (50µL) of stock HAuCl4 was mixed with 250mL of ultrapure water in a glass 
vessel. The mixture was heated with vigorous stirring until it boiled. Sodium citrate was then 
added, and the mixture was boiled until the color changed to the characteristic red color of GNPs. 
The mixture was then boiled for an additional 10 mins. The GNP solution was cooled down to 
room temperature (RT) with gentle stirring. The volume was then topped up to 250 mL with 
ultrapure water. The prepared GNP solution was stored at 4°C until used. 
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7.2.4. Preparation of GNP-Aptamer Conjugates 
GNP solution was spun down at 12,000 rpm and concentrated 5-fold in ultra-pure water. 
To 1mL of 5-fold concentrated GNPs, dATP was added to a final concentration of 7.05µM and 
incubated at RT for 20 mins with gentle shaking. 1% SDS (15uL) was added slowly and mixture 
was incubated with shaking for 10 mins. Fifty microliters (50µL) of 2M NaCl was added at a rate 
of 3 µL every 3 mins to age the gold nanoparticles. Thiolated EpCAM detection probe and 
thiolated control probe were added to the mixture and transferred to a water bath at 60°C for a 3 
hr-incubation period. Prepared GNP-aptamer conjugates were washed with BSA solution (1% 
w/v) by centrifuging at 12,000 rpm. The wash step was repeated three times. The prepared 
conjugates were resuspended in 1mL of eluent buffer (20 mM Na3PO4·12H2O, 5% BSA, 10% 
sucrose, and 0.25% Tween-20). The GNP-aptamer conjugates were then stored at 4°C until used. 
7.2.5. Preparation of GNP-Antibody Conjugates 
GNP solution was spun down at 12,000 rpm. The pellets were collected and resuspended 
at 5-fold concentration in water with pH adjusted to 9. Twenty micrograms (20ug) of anti-EpCAM 
antibody (catalogue number ABIN4949645) was added to 1mL of 5-fold GNPs and incubated at 
4°C overnight with gentle shaking. 20% BSA solution was added to a final concentration of 1% 
BSA. The mixture was further incubated for 1hr at RT. The mixture was then spun down and 
washed 3 times with PBS 1% BSA solution. The prepared GNP-anti EpCAM conjugates were then 
resuspended in 1mL of eluent buffer and stored at 4°C until used. 
7.2.6. Preparation of Streptavidin-Biotinylated DNA Probe Conjugate 
Fifty nanomoles (50nmols) of biotinylated DNA (EpCAM capture probe or control line 
probe) was mixed with 200 µL of a 2.5 mg mL-1 solution of streptavidin and incubated at RT for 
1hr with gentle shaking. The mixture was then diluted in 15mL of PBS and transferred into a 
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centrifugal filter tube (30kDa molecular cutoff). The tube was spun at 6000 rpm for 20 mins at 
4°C. The eluent was then discarded and washing step repeated two more times. Finally, the 
streptavidin-biotinylated DNA probe conjugate left on the filter was collected, diluted to 600 µL 
with PBS and dispensed immediately. 
7.2.7. Preparation of the LFSA for Exosome Detection 
The setup for the developed GNP-based LFSA for the detection of exosomes was as shown 
in Figure 7.1. The sensor was composed of three major sections (conjugate pad, nitrocellulose 
membrane and absorption pad) immobilized on a sticky backing layer made of impermeable 
plastic. The conjugate pad was a glass fiber sheet (21mm x 300m) on which the GNP conjugates 
were pre-dispensed before the assay was performed. The glassy fiber was spongy to enhance the 
adsorption of suitable volumes of conjugate. The glassy fiber material also ensured that the 
adsorbed conjugates were released upon wetting during assay runs. The conjugate pad also served 
as the point of sample application. The nitrocellulose membrane (25 mm × 300 mm) supported the 
test and control lines DNA probes. Biotinylated EpCAM capture probe or control line probes were 
dispensed 3mm apart on the nitrocellulose membrane as the test and control lines respectively. 
Post-dispensing, the nitrocellulose membrane was dried at 37°C for 1hr and stored at 4°C until 
used. The final section of the LFSB, the absorption pad, was composed of a 17 mm × 300 mm 
cellulose fiber pad. The absorption pad wicked the assay fluids to create capillary pull during test 
performance. All three components were finally assembled on a sticky backing layer card 
(60 mm × 300 mm). The components overlapped by at least 2mm to ensure continuous fluid flow 
by capillary action. The assembled unit was then cut into strips 3mm in width using the Guillotine 
cutting module CM 4000. The cut LBSBs were kept at 4°C until used. 
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Figure 7.1. Scheme of developed GNP-based lateral flow strip aptasensor for exosome detection. 
7.2.8. Preparation of Antibody-Based LFSB for Exosome Detection 
The setup of the antibody-based LFSB was similar to that of the GNP-based LFSA, 
however, for the immunosensor, the test and control line DNA sequences were replaced with 
antibodies. Anti-EpCAM antibody (catalogue number: ABIN1684521) and goat-anti mouse IgG 
at concentrations of 1 mg mL-1 were dispensed 3 mm apart on nitrocellulose membrane as test and 
control lines respectively. The nitrocellulose membrane was dried at 37°C for 1hour. Glass fiber 
conjugate pad, the nitrocellulose membrane and absorption pads were assembled on a sticky plastic 
card and cut into 3mm wide strips. The prepared immunosensors were stored at 4◦C until used. 
7.2.9. Isolation of Exosomes from Human Plasma 
Plasma samples were provided by Dr. Brand from the University of Pittsburg. Exosomes 
were purified by ultracentrifugation in Dr. Thomas Schmittgen’s laboratory at the University of 
Florida using a modified protocol as reported by Ostenfeld.191 Plasma samples were thawed on ice 
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and diluted 1:10 with cold DPBS (pH 7.4). The samples were then subjected to centrifugation at 
2,000 x g for 15 min to remove cellular debris, and at 16,000 x g for 120 min to remove large 
membrane vesicles and apoptotic bodies. The supernatant was passed through a 0.22 µm filter, 
transferred into an ultracentrifuge tube and subjected to ultracentrifugation at 100,000 x g for 2 
hours to pellet the exosomes. The exosomes were resuspended in 75 μL of DPBS and quantified 
by nanoparticle tracking analysis. Purified exosomes were frozen at -80°C until they were shipped 
on dry ice to North Dakota State University. Upon receipt, exosomes were stored at -80°C until 
used.  
7.2.10. Assay Procedure 
Exosomes solutions were prepared in running buffer (20mM Tris HCl + 20mM MgCl2 + 
1%BSA). One hundred microliters (100µL) of the exosome solution was applied to the conjugate 
pad that had pre-dispensed GNP conjugates. The sample could migrate through the LFSB in 20 
mins. An additional 100 µL of running buffer was added to wash the strip. Washing the strip 
removed any nonspecifically adsorbed conjugates which reduced background signals. After 10 
mins, distinct red colored test and control line bands were observed with the naked eye on the 
nitrocellulose membrane. For quantitative data, the test line intensities were read with the portable 
strip reader.  
7.3. Results and Discussion  
7.3.1. Working Principle of the Developed LFSA for Exosomes Detection 
The GNP-based LFSA followed a classic sandwich assay format as depicted in Figure 7.2. 
EpCAM aptamer which served as the test line capture probe was pre-dispensed on the 
nitrocellulose membrane. The nitrocellulose membrane also supported the control line DNA probe 
which also pre-immobilized prior to running the assay. Onto the conjugate pad, GNP-aptamer 
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conjugate was dropped and air dried for 5 mins before assay was performed. Exosome samples 
prepared in running buffer was applied to the conjugate pad. The exosomes then interacted with 
the detection probe of the conjugate to form a GNP-aptamer-exosome complex. The complex 
moved along the LFSA onto the nitrocellulose membrane by capillary action. Upon reaching the 
test line the exosome component of the GNP-aptamer-exosome complex interacted with the test 
line EpCAM aptamer probe and was thus captured on the test line. The accumulation of GNPs on 
the test line gave a characteristic red band which was visible to the naked eye (Figure 7.2. a). 
Excess uncaptured GNP-aptamer conjugate moved on to the control zone where it was captured 
by the hybridization between the control probe on the conjugate and the control line capture probe. 
This resulted in a second red colored band which served as validation of assay performance. In the 
absence of target exosomes, no band was observed in the test zone, however the red band on the 
control line was observed and served as validation that assay was working properly (Figure 7.2. 
b). The amount of GNP captured on the test line was directly proportional to the concentration of 
exosomes in the test sample. The intensity of the test and control line bands were read with a 
portable strip reader for quantitative data. The strip reader took images of the strips and converted 
the pixel intensity of the bands into peaks. The peak areas were proportional to the number of 
GNPs captured on the test and control lines, and hence the amount of exosomes in the test sample. 
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Figure 7.2. Working principle of the developed GNP-based LFSA (a) Capture of exosomes 
between test line and conjugate EpCAM aptamer and the capture of excess conjugate on the control 
line (b) Assay in the absence of exosomes.  
To confirm the increased sensitivity of the GNP-based LFSA over the antibody based 
LFSB, the two setups were tested in the presence and absence of exosomes. Figure 7.3 shows 
photo images of the strips after assay were ran. It is observed, that the GNP-based LFSA showed 
an intense test line band in the presence of 0.75 x 106 exosomes µL-1 compared to the immunoassay 
which showed a very weak response in the presence of a much higher concentration of exosomes 
(2.0 x10-7 exosomes µL-1). The low dissociation constants (22.8±6.0 nM) 189 of the reported 
EpCAM aptamer resulted in more efficient binding to target exosomes which increased the 
sensitivity of the aptasensor.  
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Figure 7.3. Photo images of the developed aptamer LFS (left) and the lateral flow immunosensor 
(right) with exosome concentrations 0.75 x 106 exosomes/µL and 20 x106 exosomes/µL 
respectively. 
7.3.2. Optimization of Assay Parameters  
To attain the optimal sensitivity of the developed assay various experimental parameters 
like the membrane flow rate, test line dispense cycles, buffer composition, quantity of aptamers 
coated on the GNP and the volume of conjugates per test were optimized. The overall sensitivity 
of the developed assay relied on an interplay of these parameters.  
Firstly, the type of nitrocellulose membrane used had to be optimized. Three nitrocellulose 
membranes HF090MC100, HF135MC100 and HF180MC100 with capillary flow rate of 90 sec, 
180 sec and 3 min per 4cm of membrane as reported by the manufacturer were assessed for their 
performance on the LFSA (Figure 7.4 a). The flow rate of analyte and conjugates on the LFSA 
dictated the time frame allowed for the target and aptamers to interact. As shown in Figure 7.4. a, 
the 90-sec membrane showed the lowest signal to noise (S/N) ratio. This was the membrane with 
the fastest flow rate, and hence, the least amount of time for aptamer-target interactions. This led 
to lowered test line intensities. In the case of the 3-min membrane, the slow flow rate resulted in a 
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longer time frame for the interaction between the target exosomes and aptamers on the test line 
and conjugates. This resulted in increased background signals, thus reducing the S/N ratio. As 
observed in Figure 7.4. a, the 135sec membrane showed the best S/N ratio and was thus chosen 
for further development of the aptasensor. 
 
Figure 7.4. Optimization of assay parameters (a) Effect of membrane type on the S/N ratio of the 
assay (b) Effect of dispense times of the test line aptamer on the performance of the assay (c) Effect 
of running buffer composition on the S/N ratio of the assay. 
The next line of optimizations was the dispense times of the test line. The amount of 
aptamers immobilized on the test line had a significant effect on the performance of the LFSA. A 
streptavidin-biotinylated aptamer complex in solution was dispensed a varying number of times 
(1, 2 ,3 4, 5) and their S/N ratios for exosome detection compared (Figure 7.4. b). At low dispense 
cycles (1,2 and 3) it is observed that the S/N ratios were lowered. This was attributed to the test 
line not having enough aptamer probes to efficiently capture the target exosomes. Beyond 4 times 
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dispense of the test line, there was lowering of the S/N ratio. Overcrowding of aptamers on the test 
line led to steric hinderance that limited access of targets to aptamer binding sites. Four times 
dispense of the test line had the optimal concentration of aptamers on the test line and resulted in 
the highest S/N ratio. 
The aptamers and the targets interacted in buffers, and the composition of these buffers 
could either enhance or reduce the magnitude of these interactions. PBS (1% BSA, 30mM MgCl2), 
PBST (1% BSA, 30mM MgCl2) and 20mM Tris-HCl (1% BSA, 30mM MgCl2) were tested as 
running buffer and their S/N ration were compared (Figure 7.4. c). The added MgCl2 shielded the 
negative charge of the DNA oligomer backbones and thus stabilized binding to target exosomes 
and control line probes. The Tris-HCl (1% BSA, 30mM MgCl2) gave the best S/N ratio and was 
thus used for all subsequent test runs. 
The amount of detection probe on the GNP-aptamer conjugate was also optimized. The 
aptamers on the GNP were the first to interact with the sample exosomes. This reaction had to be 
efficient to ensure effectual exosome dependent localization of the GNP conjugates on the test line 
as test progressed. To a fixed volume of GNP, varied amounts (0.1, 0.2, 0.3, 0.4, 0.5 optical 
densities (OD)) of thiolated EpCAM detection probe were conjugated. The resultant GNP-aptamer 
conjugates were tested for their performance on the developed aptasensor (Figure 7.5. a). At 0.1 
OD it was rationalized that insufficient detection probe immobilization on the GNP surface led to 
the lowered S/N ratio recorded. The highest S/N ratio was observed when0.2 OD detection probe 
was used for conjugate preparation. Beyond 0.2OD the S/N ratio declined. The decline in S/N ratio 
may have been because of overcrowding of aptamers on the GNP surface which hindered the 
access of exosomes to the detection probe. 0.2 OD detection probe was subsequently used for 
further conjugate preparation and testing. 
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Figure 7.5. (a) Effect of the amount of EpCAM aptamer used for conjugate preparation on the 
performance of the GNP-based LFSA (b) Effect of conjugate volume on the S/N ratio of the assay. 
The final optimization performed was the volume of GNP-aptamer conjugates dispensed 
on the conjugate pad prior to running the assay. Figure 7.5. b shows a series of volumes (1, 2, 3 
,4, 5 and 6 µL) of GNP-aptamer conjugates were tested and their S/N ratios compared. At low 
volumes (1, 2 and 3 µL) the amount of GNP-aptamer conjugates present was low, and this resulted 
in lowered test line intensities and thus the observed lower S/N ratios. Beyond 4 µL, there was a 
decline in the S/N ratio due to increased background signals resultant of increased nonspecific 
adsorption. The highest S/N ratio was observed when 4 µL GNP-aptamer conjugate was used per 
test-run. 4 µL conjugate volume was used for further development of the assay. 
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7.3.3. Analytical Performance 
Under optimized conditions [nitrocellulose membrane (135sec membrane), dispense 
cycles of test line (4 times), running buffer (Tris-HCl + 1% BSA + 30mM MgCl2), detection probe 
for conjugate preparation (0.2 OD) and conjugate volume (4µL)], the developed GNP-based LFSA 
was used to analyze exosome solutions ranging from 0.0 to 1.0 x 106 exosomes µL-1 of running 
buffer. All tests were run in triplicate with test line intensities read and averaged for each 
concentration. Figure 7.6. a shows typical images for the detection assay and as expected the test 
line intensities increased with increasing concentration of exosomes. The blank sample had no 
observable test line band. It was thus concluded that the optimization process did not result in any 
significant non-specific adsorption. 
The test line intensities were read with a portable strip reader and their intensities had a 
good linear relationship (R2 = 0.9921) with the exosome concentration (Figure 7.6. b). The GNP-
based LFSA had a wide dynamic range of 5.0 x104 to 1.0 x 106 exosomes µL-1 of solution. The 
calibration equation was y = 776.62x + 36.59, where y and x represent the test line intensities and 
concentrations of exosomes respectively. 
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Figure 7.6. (a) Typical images of GNP-based LFSA in the presence of varying concentration of 
exosomes (b) Calibration curve for developed aptasensor. 
The detection limit of the assay was 1.3 x 10-4 exosomes µL-1 (S/N ratio =3). The developed 
assay showed over 60-fold lower detection limit than previous report using antibodies to detect 
exosomes on a LFSB. 72 Aside the low detection limit achieved, the GNP-based LFSA showed 
very good reproducibility. The reproducibility of the assay was evaluated by running the assay in 
the absence and the presence of 1.0 x105 and 5x 105 exosome µL-1. For each concentration, six 
replicate tests were performed. The test line intensities were measured with the portable reader and 
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their intensities averaged. The relative standard deviation at 0, 1.0 x105 and 5x 105 exosomes µL-
1 were calculated to be 5.3%, 6.6% and 7.2% respectively (data not shown). 
7.4. Conclusion 
In this work, a quantitative GNP-based lateral flow strip aptasensor was successfully 
developed for the rapid and sensitive detection of exosomes. The aptasensor achieved a detection 
limit of 1.3 x 104 exosome µL-1which was about 60-fold lower than previous reports of exosomes 
on an antibody- based LFSB.72 The assay had a linear dynamic range from 5.0 x 104 to 1.0 x 106 
exosomes µL. The developed GNP-based LFSA offers an inexpensive, quick and sensitive method 
for the detection of exosomes by utilizing their EpCAM expression profiles. Upon further 
development and validation, the developed assay may find clinical application in cancer screening 
and monitoring. 
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8. SUMMARY AND CONCLUSIONS 
 In clinical practice, cancer diagnosis has been done using complex and expensive 
instrumental methods such as computer tomography scans, angiography and magnetic resonance 
imaging. Other methods like laparoscopy and needle biopsies have also been used to diagnose 
cancer. These methods are not ideal for routine disease diagnosis and disease monitoring. This 
dissertation aimed to develop lateral flow strip biosensors for the detection of cancer biomarkers 
in human plasma to help in the routine screening of cancer. The LFSB platform was chosen 
because they are inexpensive and hence do not require expensive equipment and skilled labor for 
operation. The developed LFSBs have the added advantages of being rapid, sensitive and required 
small volumes of sample. GNP- based LFSB was each developed for the screening of CA 19-9, 
CEA and exosomes in clinical samples. Further, based on previous work that showed improvement 
in sensitivity of DNA detection when MWCNT replaced traditional GNPs as transducers on the 
LFSB, MWCNT-based LFSBs were developed for the detection of CA 19-9 and CEA.  
The following lateral flow biosensors are reported in this dissertation: 
• GNPs were used as labels for the detection of CA 19-9. The GNPs efficiently 
loaded anti-CA 19-9 antibodies to enable the sensitive detection of CA 19-9. After 
systematic optimizations a visual detection limit of 5 U mL-1 was achieved which 
was below the reference value of 37 U mL-1. The developed GNP-based LFSB was 
successfully applied for the screening of CA-19-9 in human plasma. The assay 
showed good performance with results confirmed by commercial ELISA. 
• A GNP-based LFSB was developed for the detection of CEA in pancreatic cyst 
fluid. The assay showed good sensitivity with a detection limit of 2 ng mL-1 
(S/N=3). This detection limit was much lower than the CEA reference value of 192 
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ng mL-1 in pancreatic cyst fluid. The developed biosensor was successfully used to 
distinguished mucinous  from non-mucinous pancreatic cyst fluid.  
• As proof of concept, a quantitative MWCNT-based LFSB was developed for the 
detection of proteins in human plasma. Rabbit IgG was used as a model target. Goat 
anti-Rabbit IgG was covalently loaded onto MWCNT and used to detect rabbit IgG. 
The enhanced loading of antibodies along with the intense black color of the 
MWCNTs enabled the attainment of an ultra-low detection limit of 1.32 pg mL-1 
rabbit IgG. This was an over 1500-fold improvement over the GNP-based LFSB. 
The assay was successfully applied for the detection of Rabbit IgG spiked into 
human plasma. Based on the good performance of the MWCNT-based LFSB for 
protein detection, MWCNT based LFSBs were developed for the detection of CEA 
and CA 19-9. These biosensors also showed improvement over the GNP-based 
LFSBs. The MWCNT-based LFSB for the detection of CA 19-9 showed a detection 
limit of 0.14 U mL-1 which was about 35-fold lower than that of the GNP-based 
system. The MWCNT-based LFSB for CEA detection, showed a detection limit of 
0.1ng mL-1 which was a 20-fold improvement over the corresponding GNP-based 
assay for CEA detection. 
• Exosomes were detected by aptamers previously developed for EpCAM, a cell 
surface protein that has been reported to be elevated in pancreatic cancer patients. 
The EpCAM aptamer was successfully coated onto the surface of GNPs and applied 
for the detection of exosomes isolated from human plasma. The developed GNP-
based lateral flow aptasensor had a detection limit of 1.3 x 104 exosome µL-1which 
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was about 60-fold lower than previous report of exosome detection on lateral flow 
strip immunosensor.72  
The developed sensors show good sensitivity, however future work must be performed to 
further validate the assays using larger sample sizes. Also, to increase future prospects for the 
commercialization of the developed assays, batch-to-batch variability of the LFSBs has to be 
examined. In the future, the developed MWCNT-based LFSBs for the detection of CA 19-9 and 
CEA will have to be assessed for their performance at screening clinical samples. Overall, the 
work presented in this dissertation successfully developed lateral flow strip biosensors for the 
rapid, inexpensive and sensitive detection of cancer biomarkers. The assays show great promise 
for application in routine cancer screening, particularly in limited resource settings. 
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